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PREAMBLE
The American College of Cardiology (ACC) and the
American Heart Association (AHA) are committed to the
prevention and management of cardiovascular diseases
through professional education and research for clini-
cians, providers, and patients. Since 1980, the ACC and
AHA have shared a responsibility to translate scientiﬁc
evidence into clinical practice guidelines (CPGs) with
recommendations to standardize and improve cardio-
vascular health. These CPGs, based on systematic
methods to evaluate and classify evidence, provide a
cornerstone of quality cardiovascular care.
In response to published reports from the Institute of
Medicine (1,2) and the ACC/AHA’s mandate to evaluate
new knowledge and maintain relevance at the point of
care, the ACC/AHA Task Force on Practice Guidelines
(Task Force) began modifying its methodology. This
modernization effort is published in the 2012 Methodol-
ogy Summit Report (3) and 2014 perspective article (4).
The Latter recounts the history of the collaboration,
changes over time, current policies, and planned initia-
tives to meet the needs of an evolving health-care envi-
ronment. Recommendations on value in proportion to
resource utilization will be incorporated as high-quality
comparative-effectiveness data become available (5).
The relationships between CPGs and data standards,
appropriate use criteria, and performance measures are
addressed elsewhere (4).
Intended Use—CPGs provide recommendations appli-
cable to patients with or at risk of developing cardiovas-
cular disease. The focus is on medical practice in the
United States, but CPGs developed in collaboration with
other organizations may have a broader target. Although
CPGs may be used to inform regulatory or payer decisions,
the intent is to improve quality of care and be aligned
with the patient’s best interest.
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members are charged with reviewing the literature;
weighing the strength and quality of evidence for or
against particular tests, treatments, or procedures; and
estimating expected health outcomes when data exist. In
analyzing the data and developing CPGs, the GWC uses
evidence-based methodologies developed by the Task
Force (6). A key component of the ACC/AHA CPG method-
ology is the development of recommendations on the
basis of all available evidence. Literature searches focus
on randomized controlled trials (RCTs) but also include
registries, nonrandomized comparative and descriptive
studies, case series, cohort studies, systematic reviews,
and expert opinion. Only selected references are cited in
the CPG. To ensure that CPGs remain current, new data
are reviewed biannually by the GWCs and the Task Force
to determine if recommendations should be updated or
modiﬁed. In general, a target cycle of 5 years is planned for
full revision (1).
The Task Force recognizes the need for objective, in-
dependent Evidence Review Committees (ERCs) to
address key clinical questions posed in the PICOTS
format (P ¼ population; I ¼ intervention; C ¼ comparator;
O ¼ outcome; T ¼ timing; S ¼ setting). The ERCs include
methodologists, epidemiologists, clinicians, and bio-
statisticians who systematically survey, abstract, and
assess the quality of the evidence base (3,4). Practical
considerations, including time and resource constraints,
limit the ERCs to addressing key clinical questions for
which the evidence relevant to the guideline topic lends
itself to systematic review and analysis when the system-
atic review could impact the sense or strength of related
recommendations. The GWC develops recommendations
on the basis of the systematic review and denotes them
with superscripted “SR” (i.e., SR) to emphasize support
derived from formal systematic review.
Guideline-Directed Medical Therapy—Recognizing ad-
vances in medical therapy across the spectrum of car-
diovascular diseases, the Task Force designated the term
“guideline-directed medical therapy” (GDMT) to repre-
sent recommended medical therapy as deﬁned mainly by
Class I measures—generally a combination of lifestyle
modiﬁcation and drug- and device-based therapeutics. As
medical science advances, GDMT evolves, and hence
GDMT is preferred to “optimal medical therapy.” For
GDMT and all other recommended drug treatment regi-
mens, the reader should conﬁrm the dosage with product
insert material and carefully evaluate for contraindica-
tions and possible drug interactions. Recommendations
are limited to treatments, drugs, and devices approved for
clinical use in the United States.
Class of Recommendation and Level of Evidence—
Once recommendations are written, the Class of Recom-
mendation (COR; i.e., the strength the GWC assigns to therecommendation, which encompasses the anticipated
magnitude and judged certainty of beneﬁt in proportion
to risk) is assigned by the GWC. Concurrently, the Level of
Evidence (LOE) rates the scientiﬁc evidence supporting
the effect of the intervention on the basis of the type,
quality, quantity, and consistency of data from clinical
trials and other reports (Table 1) (4).
Relationships With Industry and Other Entities—The
ACC and AHA exclusively sponsor the work of GWCs,
without commercial support, and members volunteer
their time for this activity. The Task Force makes every
effort to avoid actual, potential, or perceived conﬂicts of
interest that might arise through relationships with in-
dustry or other entities (RWI). All GWC members and
reviewers are required to fully disclose current industry
relationships or personal interests, from 12 months
before initiation of the writing effort. Management of
RWI involves selecting a balanced GWC and requires that
both the chair and a majority of GWC members have no
relevant RWI (see Appendix 1 for the deﬁnition of rele-
vance). GWC members are restricted with regard to
writing or voting on sections to which their RWI apply.
In addition, for transparency, GWC members’ compre-
hensive disclosure information is available as an online
supplement. Comprehensive disclosure information for
the Task Force is also available as an online supplement.
The Task Force strives to avoid bias by selecting experts
from a broad array of backgrounds representing different
geographic regions, genders, ethnicities, intellectual
perspectives/biases, and scopes of clinical practice.
Selected organizations and professional societies with
related interests and expertise are invited to participate
as partners or collaborators.
Individualizing Care in Patients With Associated Con-
ditions and Comorbidities—The ACC and AHA recognize
the complexity of managing patients with multiple
conditions, compared with managing patients with a
single disease, and the challenge is compounded when
CPGs for evaluation or treatment of several coexisting
illnesses are discordant or interacting (7). CPGs attempt to
deﬁne practices that meet the needs of patients in most,
but not all, circumstances and do not replace clinical
judgment.
Clinical Implementation—Management in accordance
with CPG recommendations is effective only when fol-
lowed; therefore, to enhance the patient’s commitment
to treatment and compliance with lifestyle adjustment,
clinicians should engage the patient to participate in
selecting interventions on the basis of the patient’s in-
dividual values and preferences, taking associated con-
ditions and comorbidities into consideration (e.g.,
shared decision making). Consequently, there are cir-
cumstances in which deviations from these CPGs are
appropriate.
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important key clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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e81The recommendations in this CPG are the ofﬁcial policy
of the ACC and AHA until they are superseded by a pub-
lished addendum, focused update, or revised full-text CPG.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this CPG are, whenever
possible, evidence based. In April 2013, an extensive ev-
idence review was conducted, which included a literaturereview through July 2013. Other selected references
published through May 2014 were also incorporated
by the GWC. Literature included was derived from
research involving human subjects, published in English,
and indexed in MEDLINE (through PubMed), EMBASE,
the Cochrane Library, Agency for Healthcare Research and
Quality Reports, and other selected databases relevant to
this CPG. The relevant data are included in evidence
tables in the Data Supplement available online. Key
search words included but were not limited to the
following: anesthesia protection; arrhythmia; atrial ﬁbril-
lation; atrioventricular block; bundle branch block; cardiac
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electronic device; conduction disturbance; dysrhythmia;
electrocardiography; electrocautery; electromagnetic in-
terference; heart disease; heart failure; implantable
cardioverter-deﬁbrillator; intraoperative; left ventricular
ejection fraction; left ventricular function; myocardial
infarction; myocardial protection; National Surgical Qual-
ity Improvement Program; pacemaker; perioperative;
perioperative pain management; perioperative risk; post-
operative; preoperative; preoperative evaluation; surgical
procedures; ventricular premature beats; ventricular
tachycardia; and volatile anesthetics.
An independent ERC was commissioned to perform a
systematic review of a key question, the results of which
were considered by the GWC for incorporation into this
CPG. See the systematic review report published in
conjunction with this CPG (8) and its respective data
supplements.
1.2. Organization of the GWC
The GWC was composed of clinicians with content and
methodological expertise, including general cardiologists,
subspecialty cardiologists, anesthesiologists, a surgeon, a
hospitalist, and a patient representative/lay volunteer.
The GWC included representatives from the ACC, AHA,
American College of Surgeons, American Society of An-
esthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, Heart Rhythm
Society (HRS), Society for Cardiovascular Angiography
and Interventions, Society of Cardiovascular Anesthesi-
ologists, and Society for Vascular Medicine.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
from the ACC and the AHA; 1 reviewer each from the
American College of Surgeons, American Society of An-
esthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, HRS, Society for
Cardiovascular Angiography and Interventions, Society of
Cardiovascular Anesthesiologists, Society of Hospital
Medicine, and Society for Vascular Medicine; and 24 in-
dividual content reviewers (including members of the
ACC Adult Congenital and Pediatric Cardiology Section
Leadership Council, ACC Electrophysiology Section
Leadership Council, ACC Heart Failure and Transplant
Section Leadership Council, ACC Interventional Section
Leadership Council, and ACC Surgeons’ Council). Re-
viewers’ RWI information was distributed to the GWC and
is published in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and the AHA and endorsed
by the American College of Surgeons, American Society of
Anesthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, Heart RhythmSociety, Society for Cardiovascular Angiography and In-
terventions, Society of Cardiovascular Anesthesiologists,
Society of Hospital Medicine, and Society of Vascular
Medicine.
1.4. Scope of the CPG
The focus of this CPG is the perioperative cardiovascular
evaluation and management of the adult patient under-
going noncardiac surgery. This includes preoperative risk
assessment and cardiovascular testing, as well as (when
indicated) perioperative pharmacological (including
anesthetic) management and perioperative monitoring
that includes devices and biochemical markers. This CPG
is intended to inform all the medical professionals
involved in the care of these patients. The preoperative
evaluation of the patient undergoing noncardiac surgery
can be performed for multiple purposes, including
1) assessment of perioperative risk (which can be used to
inform the decision to proceed or the choice of surgery
and which includes the patient’s perspective), 2) deter-
mination of the need for changes in management, and
3) identiﬁcation of cardiovascular conditions or risk fac-
tors requiring longer-term management. Changes in
management can include the decision to change medical
therapies, the decision to perform further cardiovascular
interventions, or recommendations about postoperative
monitoring. This may lead to recommendations and dis-
cussions with the perioperative team about the optimal
location and timing of surgery (e.g., ambulatory surgery
center versus outpatient hospital, or inpatient admission)
or alternative strategies.
The key to optimal management is communication
among all of the relevant parties (i.e., surgeon, anesthe-
siologist, primary caregiver, and consultants) and the
patient. The goal of preoperative evaluation is to promote
patient engagement and facilitate shared decision making
by providing patients and their providers with clear, un-
derstandable information about perioperative cardiovas-
cular risk in the context of the overall risk of surgery.
The Task Force has chosen to make recommendations
about care management on the basis of available evidence
from studies of patients undergoing noncardiac surgery.
Extrapolation from data from the nonsurgical arena or
cardiac surgical arena was made only when no other data
were available and the beneﬁts of extrapolating the data
outweighed the risks.
During the initiation of the writing effort, concern was
expressed by Erasmus University about the scientiﬁc
integrity of studies led by Poldermans (9). The GWC
reviewed 2 reports from Erasmus University published on
the Internet (9,10), as well as other relevant articles on
this body of scientiﬁc investigation (11–13). The 2012
report from Erasmus University concluded that the
conduct in the DECREASE (Dutch Echocardiographic
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phy) IV and V trials “was in several respects negligent and
scientiﬁcally incorrect” and that “essential source docu-
ments are lacking” to make conclusions about other
studies led by Poldermans (9). Additionally, Erasmus
University was contacted to ensure that the GWC had up-
to-date information. On the basis of the published infor-
mation, discussions between the Task Force and GWC
leadership ensued to determine how best to treat any
study in which Poldermans was the senior investigator
(i.e., either the ﬁrst or last author). The Task Force
developed the following framework for this document:
1. The ERC will include the DECREASE trials in the
sensitivity analysis, but the systematic review report
will be based on the published data on perioperative
beta blockade, with data from all DECREASE trials
excluded.
2. The DECREASE trials and other derivative studies by
Poldermans should not be included in the CPG data
supplements and evidence tables.
3. If nonretracted DECREASE publications and/or other
derivative studies by Poldermans are relevant to the
topic, they can only be cited in the text with a comment
about the ﬁnding compared with the current recom-
mendation but should not form the basis of that
recommendation or be used as a reference for the
recommendation.
The Task Force and the GWC believe that it is crucial, for the
sake of transparency, to include the nonretracted publica-
tions in the text of the document. This is particularly
important because further investigation is occurring simul-
taneously with deliberation of the CPG recommendations.
Because of the availability of new evidence and the inter-
national impact of the controversy about the DECREASE
trials, the ACC/AHA and European Society of Cardiology/
European Society of Anesthesiology began revising their
respective CPGs concurrently. The respective GWCs per-
formed their literature reviews and analyses independently
and then developed their recommendations. Once peer re-
view of both CPGs was completed, the GWCs chose to discuss
their respective recommendations for beta-blocker therapy
and other relevant issues. Any differences in recommenda-
tions were discussed and clearly articulated in the text;
however, the GWCs aligned a few recommendations to avoid
confusion within the clinical community, except where in-
ternational practice variation was prevalent.
In developing this CPG, the GWC reviewed prior pub-
lished CPGs and related statements. Table 2 lists these
publications and statements deemed pertinent to this
effort and is intended for use as a resource. However,
because of the availability of new evidence, the current
CPG may include recommendations that supersede those
previously published.1.5. Deﬁnitions of Urgency and Risk
In describing the temporal necessity of operations in this
CPG, the GWC developed the following deﬁnitions by
consensus. An emergency procedure is one in which life or
limb is threatened if not in the operating room where
there is time for no or very limited or minimal clinical
evaluation, typically within <6 hours. An urgent proce-
dure is one in which there may be time for a limited
clinical evaluation, usually when life or limb is threatened
if not in the operating room, typically between 6 and 24
hours. A time-sensitive procedure is one in which a delay
of >1 to 6 weeks to allow for an evaluation and signiﬁcant
changes in management will negatively affect outcome.
Most oncologic procedures would fall into this category.
An elective procedure is one in which the procedure could
be delayed for up to 1 year. Individual institutions may
use slightly different deﬁnitions, but this framework
could be mapped to local categories. A low-risk procedure
is one in which the combined surgical and patient char-
acteristics predict a risk of a major adverse cardiac event
(MACE) of death or myocardial infarction (MI) of <1%.
Selected examples of low-risk procedures include cataract
and plastic surgery (34,35). Procedures with a risk of
MACE of $1% are considered elevated risk. Many previous
risk-stratiﬁcation schema have included intermediate-
and high-risk classiﬁcations. Because recommendations
for intermediate- and high-risk procedures are similar,
classiﬁcation into 2 categories simpliﬁes the recommen-
dations without loss of ﬁdelity. Additionally, a risk
calculator has been developed that allows more precise
calculation of surgical risk, which can be incorporated
into perioperative decision making (36). Approaches to
establishing low and elevated risk are developed more
fully in Section 3.
2. CLINICAL RISK FACTORS
2.1. Coronary Artery Disease
Perioperative mortality and morbidity due to coronary
artery disease (CAD) are untoward complications of
noncardiac surgery. The incidence of cardiac morbidity
after surgery depends on the deﬁnition, which ranges
from elevated cardiac biomarkers alone to the more
classic deﬁnition with other signs of ischemia (37–39). In a
study of 15 133 patients who were >50 years of age and
had noncardiac surgery requiring an overnight admission,
an isolated peak troponin T value of $0.02 ng/mL
occurred in 11.6% of patients. The 30-day mortality rate in
this cohort with elevated troponin T values was 1.9% (95%
conﬁdence interval [CI]: 1.7% to 2.1%) (40).
MACE after noncardiac surgery is often associated with
prior CAD events. The stability and timing of a recent MI
impact the incidence of perioperative morbidity and
mortality. An older study demonstrated very high
TABLE 2 Associated CPGs and Statements
Title Organization
Publication Year
(Reference)
CPGs
Management of patients with atrial ﬁbrillation AHA/ACC/HRS 2014 (14)
Management of valvular heart disease AHA/ACC 2014 (15)
Management of heart failure ACC/AHA 2013 (16)
Performing a comprehensive transesophageal echocardiographic examination ASE/SCA 2013 (17)
Management of ST-elevation myocardial infarction ACC/AHA 2013 (18)
Diagnosis and management of patients with stable ischemic heart disease ACC/AHA/AATS/PCNA/SCAI/STS 2012 (18a)
2014 (19)
Focused update incorporated into the 2007 guidelines for the management of
patients with unstable angina/non–ST-elevation myocardial infarction*
ACC/AHA 2012 (20)
Red blood cell transfusion AABB 2012 (21)
Management of patients with peripheral artery disease:
focused update and guideline
ACC/AHA 2011 (22)
2006 (23)
Diagnosis and treatment of hypertrophic cardiomyopathy ACC/AHA 2011 (24)
Coronary artery bypass graft surgery ACC/AHA 2011 (25)
Percutaneous coronary intervention ACC/AHA/SCAI 2011 (26)
Perioperative transesophageal echocardiography American Society of Anesthesiologists/SCA 2010 (27)
Management of adults with congenital heart disease ACC/AHA 2008 (28)
Statements
Perioperative beta blockade in noncardiac surgery: a systematic review ACC/AHA 2014 (8)
Basic perioperative transesophageal echocardiography examination ASE/SCA 2013 (29)
Practice advisory for preanesthesia evaluation American Society of Anesthesiologists 2012 (30)
Cardiac disease evaluation and management among kidney and liver
transplantation candidates
AHA/ACC 2012 (31)
Inclusion of stroke in cardiovascular risk prediction instruments AHA/American Stroke Association 2012 (32)
Perioperative management of patients with implantable deﬁbrillators, pacemakers
and arrhythmia monitors: facilities and patient management
HRS/American Society of Anesthesiologists 2011 (33)
*The 2012 UA/NSTEMI CPG (20) is considered policy at the time of publication of this CPG; however, a full, revised CPG will be published in 2014.
AABB indicates American Association of Blood Banks; AATS, American Association for Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; ASE,
American Society of Echocardiography; CPG, clinical practice guideline; HRS, Heart Rhythm Society; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardio-
vascular Angiography and Interventions; SCA, Society of Cardiovascular Anesthesiologists; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; and
UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
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angina (41). A study using discharge summaries demon-
strated that the postoperative MI rate decreased sub-
stantially as the length of time from MI to operation
increased (0 to 30 days ¼ 32.8%; 31 to 60 days ¼ 18.7%; 61
to 90 days ¼ 8.4%; and 91 to 180 days ¼ 5.9%), as did
the 30-day mortality rate (0 to 30 days ¼ 14.2%; 31
to 60 days ¼ 11.5%; 61 to 90 days ¼ 10.5%; and 91 to
180 days ¼ 9.9%) (42). This risk was modiﬁed by the
presence and type of coronary revascularization (coro-
nary artery bypass grafting [CABG] versus percutaneous
coronary interventions [PCIs]) that occurred at the time of
the MI (43). Taken together, the data suggest that $60
days should elapse after a MI before noncardiac surgery in
the absence of a coronary intervention. A recent MI,
deﬁned as having occurred within 6 months of noncardiac
surgery, was also found to be an independent risk factorfor perioperative stroke, which was associated with an
8-fold increase in the perioperative mortality rate (44).
A patient’s age is an important consideration, given
that adults (those $55 years of age) have a growing prev-
alence of cardiovascular disease, cerebrovascular disease,
and diabetes mellitus (45), which increase overall risk for
MACE when they undergo noncardiac surgery. Among
older adult patients (those >65 years of age) undergoing
noncardiac surgery, there was a higher reported incidence
of acute ischemic stroke than for those #65 years of
age (46). Age >62 years is also an independent risk factor
for perioperative stroke (44). More postoperative compli-
cations, increased length of hospitalization, and inability
to return home after hospitalization were also more pro-
nounced among “frail” (e.g., those with impaired cogni-
tion and with dependence on others in instrumental
activities of daily living), older adults>70 years of age (47).
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predict perioperative MACE (32).
See Online Data Supplements 1 and 2 for additional
information on CAD and the inﬂuence of age and sex. An
extensive consideration of CAD in the context of noncardiac
surgery, including assessment for ischemia and other as-
pects, follows later in this document.
2.2. Heart Failure
Patients with clinical heart failure (HF) (active HF symp-
toms or physical examination ﬁndings of peripheral
edema, jugular venous distention, rales, third heart
sound, or chest x-ray with pulmonary vascular redistri-
bution or pulmonary edema) or a history of HF are at
signiﬁcant risk for perioperative complications, and
widely used indices of cardiac risk include HF as an in-
dependent prognostic variable (37,48,49).
The prevalence of HF is increasing steadily (50), likely
because of aging of the population and improved survival
with newer cardiovascular therapies. Thus, the number of
patients with HF requiring preoperative assessment is
increasing. The risk of developing HF is higher in the
elderly and in individuals with advanced cardiac disease,
creating the likelihood of clustering of other risk factors
and comorbidities when HF is manifest.
2.2.1. Role of HF in Perioperative Cardiac Risk Indices
In the Original Cardiac Risk Index, 2 of the 9 independent
signiﬁcant predictors of life-threatening and fatal cardiac
complications—namely, the presence of preoperative
third heart sound and jugular venous distention—were
associated with HF and had the strongest association with
perioperative MACE (48). Subsequent approaches shifted
the emphasis to history of HF (37) and deﬁned HF by a
combination of signs and symptoms, such as history of
HF, pulmonary edema, or paroxysmal nocturnal dyspnea;
physical examination showing bilateral rales or third
heart sound gallop; and chest x-ray showing pulmonary
vascular redistribution. This deﬁnition, however, did not
include important symptoms such as orthopnea and
dyspnea on exertion (16). Despite the differences in deﬁ-
nition of HF as a risk variable, changes in demographics,
changes in the epidemiology of patients with cardiovas-
cular comorbidities, changes in treatment strategies, and
advances in the perioperative area, population-based
studies have demonstrated that HF remains a signiﬁcant
risk for perioperative morbidity and mortality. In a study
that used Medicare claims data, the risk-adjusted 30-day
mortality and readmission rate in patients undergoing 1
of 13 predeﬁned major noncardiac surgeries was 50% to
100% higher in patients with HF than in an elderly control
group without a history of CAD or HF (51,52). These results
suggest that patients with HF who undergo major surgical
procedures have substantially higher risks of operativedeath and hospital readmission than do other patients. In
a population-based data analysis of 4 cohorts of 38 047
consecutive patients, the 30-day postoperative mortality
rate was signiﬁcantly higher in patients with nonischemic
HF (9.3%), ischemic HF (9.2%), and atrial ﬁbrillation (AF)
(6.4%) than in those with CAD (2.9%) (53). These ﬁnd-
ings suggest that although perioperative risk-prediction
models place greater emphasis on CAD than on HF, pa-
tients with active HF have a signiﬁcantly higher risk of
postoperative death than do patients with CAD. Further-
more, the stability of a patient with HF plays a signiﬁcant
role. In a retrospective single-center cohort study of pa-
tients with stable HF who underwent elective noncardiac
surgery between 2003 and 2006, perioperative mortality
rates for patients with stable HF were not higher than for
the control group without HF, but these patients with
stable HF were more likely than patients without HF to
have longer hospital stays, require hospital readmission,
and have higher long-term mortality rates (54). However,
all patients in this study were seen in a preoperative
assessment, consultation, and treatment program; and the
population did not include many high-risk patients. These
results suggest improved perioperative outcomes for pa-
tients with stable HF who are treated according to GDMT.
2.2.2. Risk of HF Based on Left Ventricular Ejection Fraction:
Preserved Versus Reduced
Although signs and/or symptoms of decompensated
HF confer the highest risk, severely decreased (<30%)
left ventricular ejection fraction (LVEF) itself is an in-
dependent contributor to perioperative outcome and a
long-term risk factor for death in patients with HF un-
dergoing elevated-risk noncardiac surgery (55). Survival
after surgery for those with a LVEF #29% is signiﬁcantly
worse than for those with a LVEF >29% (56). Studies have
reported mixed results for perioperative risk in patients
with HF and preserved LVEF, however. In a meta-analysis
using individual patient data, patients with HF and pre-
served LVEF had a lower all-cause mortality rate than did
of those with HF and reduced LVEF (the risk of death did
not increase notably until LVEF fell below 40%) (57).
However, the absolute mortality rate was still high in
patients with HF and preserved LVEF as compared with
patients without HF, highlighting the importance of
presence of HF. There are limited data on perioperative
risk stratiﬁcation related to diastolic dysfunction. Dia-
stolic dysfunction with and without systolic dysfunction
has been associated with a signiﬁcantly higher rate of
MACE, prolonged length of stay, and higher rates of
postoperative HF (58,59).
2.2.3. Risk of Asymptomatic Left Ventricular Dysfunction
Although symptomatic HF is a well-established peri-
operative cardiovascular risk factor, the effect of
Fleisher et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
ACC/AHA Perioperative Clinical Practice Guideline D E C E M B E R 9 , 2 0 1 4 : e 7 7 – 1 3 7
e86asymptomatic left ventricular (LV) dysfunction on peri-
operative outcomes is unknown. In 1 prospective cohort
study on the role of preoperative echocardiography in
1005 consecutive patients undergoing elective vascular
surgery at a single center, LV dysfunction (LVEF <50%)
was present in 50% of patients, of whom 80% were
asymptomatic (58). The 30-day cardiovascular event rate
was highest in patients with symptomatic HF (49%), fol-
lowed by those with asymptomatic systolic LV dysfunc-
tion (23%), asymptomatic diastolic LV dysfunction (18%),
and normal LV function (10%). Further studies are
required to determine if the information obtained from
the assessment of ventricular function in patients without
signs or symptoms adds incremental information that will
result in changes in management and outcome such that
the appropriateness criteria should be updated. It should
be noted that the 2011 appropriate use criteria for echo-
cardiography states it is “inappropriate” to assess ven-
tricular function in patients without signs or symptoms
of cardiovascular disease in the preoperative setting
(60). For preoperative assessment of LV function, see
Section 5.2.
2.2.4. Role of Natriuretic Peptides in Perioperative Risk of HF
Preoperative natriuretic peptide levels independently
predict cardiovascular events in the ﬁrst 30 days after
vascular surgery (61–66) and signiﬁcantly improve the
predictive performance of the Revised Cardiac Risk Index
(RCRI) (61). Measurement of biomarkers, especially
natriuretic peptides, may be helpful in assessing patients
with HF and with diagnosing HF as a postoperative
complication in patients at high risk for HF. Further pro-
spective randomized studies are needed to assess the
utility of such a strategy (Section 3.1).
2.3. Cardiomyopathy
There is little information on the preoperative evaluation
of patients with speciﬁc nonischemic cardiomyopathies
before noncardiac surgery. Preoperative recommenda-
tions must be based on a thorough understanding of
the pathophysiology of the cardiomyopathy, assessment
and management of the underlying process, and overall
management of the HF.
Restrictive Cardiomyopathies: Restrictive cardiomy-
opathies, such as those associated with cardiac amyloid-
osis, hemochromatosis, and sarcoidosis, pose special
hemodynamic and management problems. Cardiac output
in these cardiomyopathies with restrictive physiology is
both preload and heart rate dependent. Signiﬁcant
reduction of blood volume or ﬁlling pressures, brady-
cardia or tachycardia, and atrial arrhythmias such as AF/
atrial ﬂutter may not be well tolerated. These patients
require a multidisciplinary approach, with optimization of
the underlying pathology, volume status, and HF statusincluding medication adjustment targeting primary dis-
ease management.
Hypertrophic Obstructive Cardiomyopathy: In hyper-
trophic obstructive cardiomyopathy, decreased systemic
vascular resistance (arterial vasodilators), volume loss, or
reduction in preload or LV ﬁlling may increase the degree
of dynamic obstruction and further decrease diastolic
ﬁlling and cardiac output, with potentially untoward re-
sults. Overdiuresis should be avoided, and inotropic
agents are usually not used in these patients because of
increased LV outﬂow gradient. Studies have reported
mixed results for perioperative risk in patients with hy-
pertrophic obstructive cardiomyopathy. Most studies
were small, were conducted at a single center, and reﬂect
variations in patient populations, types of surgery, and
management (67–69).
Arrhythmogenic Right Ventricular (RV) Cardiomyopathy
and/or Dysplasia: In 1 autopsy study examining a series
of 200 cases of sudden death associated with arrhyth-
mogenic RV cardiomyopathy and/or dysplasia, death
occurred in 9.5% of cases during the perioperative period
(70). This emphasizes the importance of close periopera-
tive evaluation and monitoring of these patients for
ventricular arrhythmia. Most of these patients require
cardiac electrophysiologist involvement and consider-
ation for an implantable cardioverter-deﬁbrillator (ICD)
for long-term management.
In a retrospective analysis of 1700 forensic autopsies of
patients with sudden, unexpected perioperative death
over 17 years, pathological examination showed cardiac
lesions in 47 cases, arrhythmogenic RV cardiomyopathy
in 18 cases, CAD in 10 cases, cardiomyopathy in 8 cases,
structural abnormalities of the His bundle in 9 cases,
mitral valve prolapse in 1 case, and acute myocarditis in 1
case, suggesting the importance of detailed clinical his-
tories and physical examinations before surgery for
detection of these structural cardiac abnormalities (71).
Peripartum Cardiomyopathy: Peripartum cardiomy-
opathy is a rare cause of dilated cardiomyopathy that
occurs in approximately 1 in 1000 deliveries and mani-
fests during the last few months of pregnancy or the ﬁrst 6
months of the postpartum period. It can result in severe
ventricular dysfunction during late puerperium (72).
Prognosis depends on the recovery of the LV contractility
and resolution of symptoms within the ﬁrst 6 months
after onset of the disease. The major peripartum concern
is to optimize ﬂuid administration and avoid myocardial
depression while maintaining stable intraoperative he-
modynamics (73). Although the majority of patients
remain stable and recover, emergency delivery may be
life-saving for the mother as well as the infant. Acute
and critically ill patients with refractory peripartum
cardiomyopathy may require mechanical support with
an intra-aortic balloon pump, extracorporeal membrane
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cardiac transplantation (74).
See Online Data Supplement 3 for additional information
on HF and cardiomyopathy.
2.4. Valvular Heart Disease: Recommendations
See the 2014 valvular heart disease CPG for the complete
set of recommendations and speciﬁc deﬁnitions of dis-
ease severity (15) and Online Data Supplement 4 for
additional information on valvular heart disease.
CLASS I
1. It is recommended that patients with clinically suspected
moderate or greater degrees of valvular stenosis or regur-
gitation undergo preoperative echocardiography if there has
been either 1) no prior echocardiography within 1 year or 2) a
signiﬁcant change in clinical status or physical examination
since last evaluation (60). (Level of Evidence: C)
2. For adults who meet standard indications for valvular
intervention (replacement and repair) on the basis of
symptoms and severity of stenosis or regurgitation, valvular
intervention before elective noncardiac surgery is effective
in reducing perioperative risk (15). (Level of Evidence: C)
Signiﬁcant valvular heart disease increases cardiac risk for
patients undergoing noncardiac surgery (37,48). Patients
with suspected valvular heart disease should undergo
echocardiography to quantify the severity of stenosis or
regurgitation, calculate systolic function, and estimate right
heart pressures. Evaluation for concurrent CAD is also war-
ranted, with electrocardiography exercise testing, stress
echocardiographic or nuclear imaging study, or coronary
angiography, as appropriate.
Emergency noncardiac surgery may occur in the pres-
ence of uncorrected signiﬁcant valvular heart disease.
The risk of noncardiac surgery can be minimized by
1) having an accurate diagnosis of the type and severity of
valvular heart disease, 2) choosing an anesthetic approach
appropriate to the valvular heart disease, and 3) consid-
ering a higher level of perioperative monitoring (e.g.,
arterial pressure, pulmonary artery pressure, trans-
esophageal echocardiography), as well as managing the
patient postoperatively in an intensive care unit setting.
2.4.1. Aortic Stenosis: Recommendation
CLASS IIa
1. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe
aortic stenosis (AS) (48,75–84). (Level of Evidence: B)
In the Original Cardiac Risk Index, severe AS was associated
with a perioperative mortality rate of 13%, compared with
1.6% in patients without AS (48). The mechanism of MACE in
patients with AS likely arises from the anesthetic agents andsurgical stress that lead to an unfavorable hemodynamic
state. The occurrence of hypotension and tachycardia can
result in decreased coronary perfusion pressure, develop-
ment of arrhythmias or ischemia, myocardial injury, cardiac
failure, and death.
With the recent advances in anesthetic and surgical
approaches, the cardiac risk in patients with signiﬁcant
AS undergoing noncardiac surgery has declined. In a
single, tertiary-center study, patients with moderate AS
(aortic valve area: 1.0 cm2 to 1.5 cm2) or severe AS (aortic
valve area <1.0 cm2) undergoing nonemergency noncar-
diac surgery had a 30-day mortality rate of 2.1%,
compared with 1.0% in propensity score–matched
patients without AS (p¼0.036) (75). Postoperative MI was
more frequent in patients with AS than in patients
without AS (3.0% versus 1.1%; p¼0.001). Patients with AS
had worse primary outcomes (deﬁned as composite of
30-day mortality and postoperative MI) than did patients
without AS (4.4% versus 1.7%; p¼0.002 for patients with
moderate AS; 5.7% versus 2.7%; p¼0.02 for patients with
severe AS). Predictors of 30-day death and postoperative
MI in patients with moderate or severe AS include high-
risk surgery (odds ratio [OR]: 7.3; 95% CI: 2.6 to 20.6),
symptomatic severe AS (OR: 2.7; 95% CI: 1.1 to 7.5),
coexisting moderate or severe mitral regurgitation (MR)
(OR: 9.8; 95% CI: 3.1 to 20.4), and pre-existing CAD (OR:
2.7; 95% CI: 1.1 to 6.2).
For patients who meet indications for aortic valve
replacement (AVR) before noncardiac surgery but are
considered high risk or ineligible for surgical AVR,
options include proceeding with noncardiac surgery with
invasive hemodynamic monitoring and optimization of
loading conditions, percutaneous aortic balloon dilation
as a bridging strategy, and transcatheter aortic valve
replacement (TAVR). Percutaneous aortic balloon dilation
can be performed with acceptable procedural safety, with
the mortality rate being 2% to 3% and the stroke rate
being 1% to 2% (76–78,84). However, recurrence and
mortality rates approach 50% by 6 months after the
procedure. Single-center, small case series from more
than 25 years ago reported the use of percutaneous aortic
balloon dilation in patients with severe AS before
noncardiac surgery (79–81). Although the results were
acceptable, there were no comparison groups or long-
term follow-up. The PARTNER (Placement of Aortic
Transcatheter Valves) RCT demonstrated that TAVR has
superior outcomes for patients who are not eligible for
surgical AVR (1-year mortality rate: 30.7% for TAVR
versus 50.7% for standard therapy) and similar efﬁcacy
for patients who are at high risk for surgical AVR (1-year
mortality rate: 24.2% for TAVR versus 26.8% for surgical
AVR) (82,83). However, there are no data for the efﬁcacy
or safety of TAVR for patients with AS who are under-
going noncardiac surgery.
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CLASS IIb
1. Elevated-risk elective noncardiac surgery using appropriate
intraoperative and postoperative hemodynamic monitoring
may be reasonable in asymptomatic patients with severe
mitral stenosis if valve morphology is not favorable
for percutaneous mitral balloon commissurotomy. (Level of
Evidence: C)
Patients with severe mitral stenosis are at increased risk for
noncardiac surgery and should be managed similarly to pa-
tients with AS. The main goals during the perioperative
period are to monitor intravascular volume and to avoid
tachycardia and hypotension. It is crucial to maintain intra-
vascular volume at a level that ensures adequate forward
cardiac output without excessive rises in left atrial pressure
and pulmonary capillary wedge pressure that could precipi-
tate acute pulmonary edema.
Patients with mitral stenosis who meet standard
indications for valvular intervention (open mitral com-
missurotomy or percutaneous mitral balloon commissur-
otomy) should undergo valvular intervention before
elective noncardiac surgery (85). If valve anatomy is not
favorable for percutaneous mitral balloon commissur-
otomy, or if the noncardiac surgery is an emergency, then
noncardiac surgery may be considered with invasive he-
modynamic monitoring and optimization of loading con-
ditions. There are no reports of the use of percutaneous
mitral balloon commissurotomy before noncardiac sur-
gery; however, this procedure has excellent outcomes
when used during high-risk pregnancies (86,87).
2.4.3. Aortic and Mitral Regurgitation: Recommendations
CLASS IIa
1. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring
is reasonable in adults with asymptomatic severe MR. (Level
of Evidence: C)
2. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring
is reasonable in adults with asymptomatic severe aortic
regurgitation (AR) and a normal LVEF. (Level of Evidence: C)
Left-sided regurgitant lesions convey increased cardiac risk
during noncardiac surgery but are better tolerated than ste-
notic valvular disease (88,89). AR and MR are associated
with LV volume overload. To optimize forward cardiac
output during anesthesia and surgery, 1) preload should be
maintained because the LV has increased size and compli-
ance, and 2) excessive systemic afterload should be avoided
so as to augment cardiac output and reduce the regurgitation
volume. For patients with severe AR or MR, the LV forward
cardiac output is reduced because of the regurgitant volume.
Patients with moderate-to-severe AR and severe AR
undergoing noncardiac surgery had a higher in-hospitalmortality rate than did case-matched controls without
AR (9.0% versus 1.8%; p¼0.008) and a higher morbidity
rate (16.2% versus 5.4%; p¼0.003), including post-
operative MI, stroke, pulmonary edema, intubation >24
hours, and major arrhythmia (88). Predictors of in-
hospital death included depressed LVEF (ejection frac-
tion [EF] <55%), renal dysfunction (creatinine >2 mg/dL),
high surgical risk, and lack of preoperative cardiac medi-
cations. In the absence of trials addressing perioperative
management, patients with moderate-to-severe AR and
severe AR could be monitored with invasive hemody-
namics and echocardiography and could be admitted
postoperatively to an intensive care unit setting when
undergoing surgical procedures with elevated risk.
In a single, tertiary-center study, patients with
moderate-to-severe MR and severe MR undergoing
nonemergency noncardiac surgery had a 30-day mortality
rate similar to that of propensity score–matched controls
without MR (1.7% versus 1.1%; p¼0.43) (89). Patients with
MR had worse primary outcomes (deﬁned as composite of
30-day death and postoperative MI, HF, and stroke) than
did patients without MR (22.2% versus 16.4%; p<0.02).
Important predictors of postoperative adverse outcomes
after noncardiac surgery were EF <35%, ischemic cause of
MR, history of diabetes mellitus, and history of carotid
endarterectomy. Patients with moderate-to-severe MR
and severe MR undergoing noncardiac surgery should be
monitored with invasive hemodynamics and echocardi-
ography and admitted postoperatively to an intensive
care unit setting when undergoing surgical procedures
with elevated risk.
2.5. Arrhythmias and Conduction Disorders
Cardiac arrhythmias and conduction disorders are com-
mon ﬁndings in the perioperative period, particularly
with increasing age. Although supraventricular and ven-
tricular arrhythmias were identiﬁed as independent risk
factors for perioperative cardiac events in the Original
Cardiac Risk Index (48), subsequent studies indicated a
lower level of risk (37,90,91). The paucity of studies that
address surgical risk conferred by arrhythmias limits the
ability to provide speciﬁc recommendations. General
recommendations for assessing and treating arrhythmias
can be found in other CPGs (14,92,93). In 1 study using
continuous electrocardiographic monitoring, asymptom-
atic ventricular arrhythmias, including couplets and
nonsustained ventricular tachycardia, were not associ-
ated with an increase in cardiac complications after
noncardiac surgery (94). Nevertheless, the presence of an
arrhythmia in the preoperative setting should prompt
investigation into underlying cardiopulmonary disease,
ongoing myocardial ischemia or MI, drug toxicity, or
metabolic derangements, depending on the nature and
acuity of the arrhythmia and the patient’s history.
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is particularly common in older patients who are likely to
be undergoing surgical procedures. Patients with a pre-
operative history of AF who are clinically stable generally
do not require modiﬁcation of medical management or
special evaluation in the perioperative period, other than
adjustment of anticoagulation (Section 6.2.7). The po-
tential for perioperative formation of left atrial thrombus
in patients with persistent AF may need to be considered
if the operation involves physical manipulation of the
heart, as in certain thoracic procedures. Ventricular ar-
rhythmias, whether single premature ventricular con-
tractions or nonsustained ventricular tachycardia, usually
do not require therapy unless they result in hemodynamic
compromise or are associated with signiﬁcant structural
heart disease or inherited electrical disorders. Although
frequent ventricular premature beats and nonsustained
ventricular tachycardia are risk factors for the develop-
ment of intraoperative and postoperative arrhythmias,
they are not associated with an increased risk of nonfatal
MI or cardiac death in the perioperative period (94,95).
However, patients who develop sustained or non-
sustained ventricular tachycardia during the periopera-
tive period may require referral to a cardiologist for
further evaluation, including assessment of their ven-
tricular function and screening for CAD.
High-grade cardiac conduction abnormalities, such as
complete atrioventricular block, if unanticipated, may
increase operative risk and necessitate temporary or
permanent transvenous pacing (96). However, patients
with intraventricular conduction delays, even in the
presence of a left or right bundle-branch block, and no
history of advanced heart block or symptoms, rarely
progress to complete atrioventricular block perioper-
atively (97). The presence of some pre-existing conduc-
tion disorders, such as sinus node dysfunction and
atrioventricular block, requires caution if perioperative
beta-blocker therapy is being considered. Isolated
bundle-branch block and bifascicular block generally do
not contraindicate use of beta blockers.
2.5.1. Cardiovascular Implantable Electronic Devices:
Recommendation
See Section 6.4 for intraoperative/postoperative man-
agement of cardiovascular implantable electronic devices
(CIEDs).
CLASS I
1. Before elective surgery in a patient with a CIED, the surgical/
procedure team and clinician following the CIED should
communicate in advance to plan perioperative management
of the CIED. (Level of Evidence: C)
The presence of a pacemaker or ICD has important implica-
tions for preoperative, intraoperative, and postoperativepatient management. Collectively termed CIEDs, these de-
vices include single-chamber, dual-chamber, and biven-
tricular hardware conﬁgurations produced by several
different manufacturers, each with different software
designs and programming features. Patients with CIEDs
invariably have underlying cardiac disease that can involve
arrhythmias, such as sinus node dysfunction, atrioventric-
ular block, AF, and ventricular tachycardia; structural heart
disease, such as ischemic or nonischemic cardiomyopathy;
and clinical conditions, such as chronic HF or inherited
arrhythmia syndromes. Preoperative evaluation of such
patients should therefore encompass an awareness not only
of the patient’s speciﬁc CIED hardware and programming,
but also of the underlying cardiac condition for which the
device was implanted. In particular, cardiac rhythm and
history of ventricular arrhythmias should be reviewed in
patients with CIEDs.
To assist clinicians with the perioperative evaluation
and management of patients with CIEDs, the HRS and the
American Society of Anesthesiologists jointly developed
an expert consensus statement published in July 2011 and
endorsed by the ACC and the AHA (33). Clinicians caring
for patients with CIEDs in the perioperative setting should
be familiar with that document and the consensus rec-
ommendations contained within.
The HRS/American Society of Anesthesiologists expert
consensus statement acknowledges that because of the
complexity of modern devices and the variety of in-
dications for which they are implanted, the perioperative
management of patients with CIEDs must be individual-
ized, and a single recommendation for all patients with
CIEDs is not appropriate (33). Effective communication
between the surgical/procedure team and the clinician
following the patient with a CIED in the outpatient setting
is the foundation of successful perioperative management
and should take place well in advance of elective pro-
cedures. The surgical/procedure team should communi-
cate with the CIED clinician/team to inform them of the
nature of the planned procedure and the type of electro-
magnetic interference (EMI) (i.e., electrocautery) likely to
be encountered. The outpatient team should formulate a
prescription for the perioperative management of the
CIED and communicate it to the surgical/procedure team.
The CIED prescription can usually be made from a
review of patient records, provided that patients are
evaluated at least annually (for pacemakers) or semi-
annually (for ICDs). In some circumstances, patients will
require additional preoperative in-person evaluation or
remote CIED interrogation. The prescription may involve
perioperative CIED interrogation or reprogramming
(including changing pacing to an asynchronous mode
and/or inactivating ICD tachytherapies), application of a
magnet over the CIED with or without postoperative
CIED interrogation, or use of no perioperative CIED
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prescriptions will depend on the nature and location of
the operative procedure, likelihood of use of monopolar
electrocautery, type of CIED (i.e., pacemaker versus ICD),
and dependence of the patient on cardiac pacing.
See Online Data Supplement 26 for additional informa-
tion on CIEDs.
2.6. Pulmonary Vascular Disease: Recommendations
CLASS I
1. Chronic pulmonary vascular targeted therapy (i.e., phos-
phodiesterase type 5 inhibitors, soluble guanylate cyclase
stimulators, endothelin receptor antagonists, and prosta-
noids) should be continued unless contraindicated or not
tolerated in patients with pulmonary hypertension who are
undergoing noncardiac surgery. (Level of Evidence: C)
CLASS IIa
1. Unless the risks of delay outweigh the potential beneﬁts,
preoperative evaluation by a pulmonary hypertension
specialist before noncardiac surgery can be beneﬁcial for
patients with pulmonary hypertension, particularly for those
with features of increased perioperative risk (100) *. (Level
of Evidence: C)
The evidence on the role of pulmonary hypertension in
perioperative mortality and morbidity in patients undergo-
ing noncardiac surgery is based on observational data and is
predominantly related to Group 1 pulmonary hypertension
(i.e., pulmonary arterial hypertension) (101–107). However,
complication rates are consistently high, with mortality rates
of 4% to 26% and morbidity rates, most notably cardiac and/
or respiratory failure, of 6% to 42% (101–106). A variety of
factors can occur during the perioperative period that may
precipitate worsening hypoxia, pulmonary hypertension, or
RV function. In addition to the urgency of the surgery and
the surgical risk category, risk factors for perioperative
adverse events in patients with pulmonary hypertension
include the severity of pulmonary hypertension symptoms,
the degree of RV dysfunction, and the performance of
surgery in a center without expertise in pulmonary hyper-
tension (101–106). Patients with pulmonary arterial hyper-
tension due to other causes, particularly with features of
increased perioperative risk, should undergo a thorough
preoperative risk assessment in a center with the necessary*Features of increased perioperative risk in patients with pulmonary hyper-
tension include: 1) diagnosis of Group 1 pulmonary hypertension (i.e., pulmo-
nary arterial hypertension), 2) other forms of pulmonary hypertension
associated with high pulmonary pressures (pulmonary artery systolic pressures
>70 mmHg) and/or moderate or greater RV dilatation and/or dysfunction and/
or pulmonary vascular resistance >3 Wood units, and 3) World Health Orga-
nization/New York Heart Association class III or IV symptoms attributable to
pulmonary hypertension (101–107).medical and anesthetic expertise in pulmonary hyperten-
sion, including an assessment of functional capacity, hemo-
dynamics, and echocardiography that includes evaluation of
RV function. Right heart catheterization can also be used
preoperatively to conﬁrm the severity of illness and distin-
guish primary pulmonary hypertension from secondary
causes of elevated pulmonary artery pressures, such as left-
sided HF. Patients should have optimization of pulmonary
hypertension and RV status preoperatively and should
receive the necessary perioperative management on a case-
by-case basis.
See Online Data Supplement 6 for additional informa-
tion on pulmonary vascular disease.
2.7. Adult Congenital Heart Disease
Several case series have indicated that performance of a
surgical procedure in patients with adult congenital heart
disease (ACHD) carries a greater risk than in the normal
population (108–113). The risk relates to the nature of the
underlying ACHD, the surgical procedure, and the ur-
gency of intervention (108–113). For more information,
readers are referred to the speciﬁc recommendations for
perioperative assessment in the ACC/AHA 2008 ACHD
CPG (28). When possible, it is optimal to perform the
preoperative evaluation of surgery for patients with
ACHD in a regional center specializing in congenital car-
diology, particularly for patient populations that appear
to be at particularly high risk (e.g., those with a prior
Fontan procedure, cyanotic ACHD, pulmonary arterial
hypertension, clinical HF, or signiﬁcant dysrhythmia).
3. CALCULATION OF RISK TO PREDICT
PERIOPERATIVE CARDIAC MORBIDITY
3.1. Multivariate Risk Indices: Recommendations
See Table 3 for a comparison of the RCRI, American Col-
lege of Surgeons National Surgical Quality Improvement
Program (NSQIP) Myocardial Infarction and Cardiac Arrest
(MICA), and American College of Surgeons NSQIP Surgical
Risk Calculator. See Online Data Supplement 7 for addi-
tional information on multivariate risk indices.
CLASS IIa
1. A validated risk-prediction tool can be useful in predicting
the risk of perioperative MACE in patients undergoing
noncardiac surgery (37,114,115). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. For patients with a low risk of perioperative MACE, further
testing is not recommended before the planned operation
(34,35). (Level of Evidence: B)
Different noncardiac operations are associated with different
risks of MACE. Operations for peripheral vascular disease are
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erative risk (116). The lowest-risk operations are generally
those without signiﬁcant ﬂuid shifts and stress. Plastic sur-
gery and cataract surgery are associated with a very low risk
of MACE (34). Some operations can have their risk lowered
by taking a less invasive approach. For example, open aortic
aneurysm repair has a high risk of MACE that is lowered
when the procedure is performed endovascularly (117). The
number of different surgical procedures makes assigning a
speciﬁc risk of a MACE to each procedure difﬁcult. In addi-
tion, performing an operation in an emergency situation is
understood to increase risk.
The RCRI is a simple, validated, and accepted tool to
assess perioperative risk of major cardiac complications
(MI, pulmonary edema, ventricular ﬁbrillation or primary
cardiac arrest, and complete heart block) (37). It has 6
predictors of risk for major cardiac complications, only 1
of which is based on the procedure—namely, “Undergoing
suprainguinal vascular, intraperitoneal, or intrathoracic
surgery.” A patient with 0 or 1 predictor(s) of risk would
have a low risk of MACE. Patients with $2 predictors of
risk would have elevated risk.
Two newer tools have been created by the American
College of Surgeons, which prospectively collected data
on operations performed in more than 525 participating
hospitals in the United States. Data on more than 1 million
operations have been used to create these risk calculators
(114) (www.riskcalculator.facs.org).
The American College of Surgeons NSQIP MICA risk-
prediction rule was created in 2011 (115), with a single
study—albeit large and multicenter—describing its deri-
vation and validation (http://www.surgicalriskcalculator.
com/miorcardiacarrest). This tool includes adjusted ORs
for different surgical sites, with inguinal hernia as the
reference group. Target complications were deﬁned as
cardiac arrest (deﬁned as “chaotic cardiac rhythm
requiring initiation of basic or advanced life support”) or
MI (deﬁned as $1 of the following: documented electro-
cardiographic ﬁndings of MI, ST elevation of $1 mm in >1
contiguous leads, new left bundle-branch block, new Q-
wave in $2 contiguous leads, or troponin >3 times normal
in setting of suspected ischemia). Using these deﬁnitions
of outcome and chart-based data collection methods, the
authors of the risk calculator derived a risk index that was
robust in the derivation and validation stages and
appeared to outperform the RCRI (which was tested in the
same dataset) in discriminative power, particularly
among patients undergoing vascular surgery.
The American College of Surgeons NSQIP Surgical Risk
Calculator uses the speciﬁc current procedural terminol-
ogy code of the procedure being performed to enable
procedure-speciﬁc risk assessment for a diverse group of
outcomes (114). The procedure is deﬁned as being an
emergency case or not an emergency case. For theAmerican College of Surgeons NSQIP, to be an emergency
case, the “principal operative procedure must be per-
formed during the hospital admission for the diagnosis
AND the surgeon and/or anesthesiologist must report the
case as emergent” (118). The calculator also includes 21
patient-speciﬁc variables (e.g., age, sex, body mass index,
dyspnea, previous MI, functional status). From this input,
it calculates the percentage risk of a MACE, death, and 8
other outcomes. This risk calculator may offer the best
estimation of surgery-speciﬁc risk of a MACE and death.
Some limitations to the NSQIP-based calculator should
be noted: It has not been validated in an external popu-
lation outside the NSQIP, and the deﬁnition of MI in-
cludes only ST-segment MIs or a large troponin bump (>3
times normal) that occurred in symptomatic patients. An
additional disadvantage is the use of the American Soci-
ety of Anesthesiology Physical Status Classiﬁcation, a
common qualitatively derived risk score used by anes-
thesiologists. This classiﬁcation has poor inter-rater reli-
ability even among anesthesiologists and may be
unfamiliar to clinicians outside that specialty (119,120).
Clinicians would also need to familiarize themselves with
the NSQIP deﬁnitions of functional status or “depen-
dence,” concepts that are thought to be important in
perioperative risk assessment algorithms but that have
not been included in multivariable risk indices to date (for
more information on functional status, see Section 4).
3.2. Inclusion of Biomarkers in Multivariable Risk Models
Several studies have examined the potential utility of
including biomarkers—most commonly preoperative na-
triuretic peptides (brain natriuretic peptide or N-terminal
probrain natriuretic peptide) and C-reactive protein—in
preoperative risk indices as an approach to identify pa-
tients at highest risk (64,121–125). These studies and 2 sub-
sequent meta-analyses suggest that biomarkers may
provide incremental predictive value (62,66). However,
most studies had signiﬁcant variation in the time frame in
which these biomarkers were obtained, were observa-
tional, did not include a control arm, and did not require
biomarkers routinely or prospectively. Furthermore, there
are no data to suggest that targeting these biomarkers
for treatment and intervention will reduce the post-
operative risk. In addition, several of these studies were
investigations conducted by Poldermans (121,126–130).
4. APPROACH TO PERIOPERATIVE
CARDIAC TESTING
4.1. Exercise Capacity and Functional Capacity
Functional status is a reliable predictor of perioperative
and long-term cardiac events. Patients with reduced
functional status preoperatively are at increased risk of
complications. Conversely, those with good functional
TABLE 3
Comparison of the RCRI, the American College of Surgeons NSQIP MICA, and the American College of Surgeons
NSQIP Surgical Risk Calculator
RCRI (131)
American College of
Surgeons NSQIP MICA (115)
American College of Surgeons
NSQIP Surgical Risk Calculator (114)
Criteria . Increasing age Age
Creatinine $2 mg/dL Creatinine >1.5 mg/dL Acute renal failure
HF . HF
. Partially or completely dependent
functional status
Functional status
Insulin-dependent diabetes mellitus . Diabetes mellitus
Intrathoracic, intra-abdominal, or
suprainguinal vascular surgery
Surgery type:
 Anorectal
 Aortic
 Bariatric
 Brain
 Breast
 Cardiac
 ENT
 Foregut/hepatopancreatobiliary
 Gallbladder/adrenal/appendix/
spleen
 Intestinal
 Neck
 Obstetric/gynecological
 Orthopedic
 Other abdomen
 Peripheral vascular
 Skin
 Spine
 Thoracic
 Vein
 Urologic
Procedure (CPT Code)
History of cerebrovascular accident or TIA . .
. . American Society of Anesthesiologists
Physical Status Class
. . Wound class
. . Ascites
. . Systemic sepsis
. . Ventilator dependent
. . Disseminated cancer
. . Steroid use
. . Hypertension
Ischemic heart disease . Previous cardiac event
. . Sex
. . Dyspnea
. . Smoker
. . COPD
. . Dialysis
. . Acute kidney injury
. . BMI
. . Emergency case
Continued on the next page
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highly functional asymptomatic patients, it is often
appropriate to proceed with planned surgery without
further cardiovascular testing.
If a patient has not had a recent exercise test before
noncardiac surgery, functional status can usually beestimated from activities of daily living (132). Functional
capacity is often expressed in terms of metabolic equiv-
alents (METs), where 1 MET is the resting or basal oxygen
consumption of a 40–year-old, 70-kg man. In the periop-
erative literature, functional capacity is classiﬁed as
excellent (>10 METs), good (7 METs to 10 METs),
TABLE 3 Continued
RCRI (131)
American College of
Surgeons NSQIP MICA (115)
American College of Surgeons
NSQIP Surgical Risk Calculator (114)
Use outside original cohort Yes No No
Sites Most often single-site studies, but ﬁndings
consistent in multicenter studies
Multicenter Multicenter
Outcome and risk factor
ascertainment
Original: research staff, multiple
subsequent studies using variety of data
collection strategies
Trained nurses, no prospective cardiac
outcome ascertainment
Trained nurses, no prospective
cardiac outcome ascertainment
Calculation method Single point per risk factor Web-based or open-source
spreadsheet for calculation
(http://www.surgicalriskcalculator.com/
miorcardiacarrest)
Web-based calculator
(www.riskcalculator.facs.org)
BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; CPT, current procedural terminology; ENT, ear, nose, and throat; HF, heart failure; NSQIP MICA, National
Surgical Quality Improvement Program Myocardial Infarction Cardiac Arrest; NSQIP, National Surgical Quality Improvement Program; RCRI, Revised Cardiac Risk Index; TIA, transient
ischemic attack; and ., not applicable.
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known. Perioperative cardiac and long-term risks are
increased in patients unable to perform 4 METs of work
during daily activities. Examples of activities associated
with <4 METs are slow ballroom dancing, golﬁng with a
cart, playing a musical instrument, and walking at
approximately 2 mph to 3 mph. Examples of activities
associated with >4 METs are climbing a ﬂight of stairs or
walking up a hill, walking on level ground at 4 mph, and
performing heavy work around the house.
Functional status can also be assessed more formally
by activity scales, such as the DASI (Duke Activity Status
Index) (Table 4) (133) and the Speciﬁc Activity Scale
(134). In 600 consecutive patients undergoing non-
cardiac surgery, perioperative myocardial ischemia and
cardiovascular events were more common in those with
poor functional status (deﬁned as the inability to walk 4
blocks or climb 2 ﬂights of stairs) even after adjustmentTABLE 4 Duke Activity Status Index
Activity
Can you.
1. take care of yourself, that is, eating, dressing, bathing, or using the toilet?
2. walk indoors, such as around your house?
3. walk a block or 2 on level ground?
4. climb a ﬂight of stairs or walk up a hill?
5. run a short distance?
6. do light work around the house like dusting or washing dishes?
7. do moderate work around the house like vacuuming, sweeping ﬂoors, or carrying i
8. do heavy work around the house like scrubbing ﬂoors or lifting or moving heavy f
9. do yardwork like raking leaves, weeding, or pushing a power mower?
10. have sexual relations?
11. participate in moderate recreational activities like golf, bowling, dancing, doubles
12. participate in strenuous sports like swimming, singles tennis, football, basketball,
Reproduced with permission from Hlatky et al. (133).for other risk factors (132). The likelihood of a serious
complication was inversely related to the number of
blocks that could be walked (p¼0.006) or ﬂights of stairs
that could be climbed (p¼0.01). Analyses from the
American College of Surgeons NSQIP dataset have shown
that dependent functional status, based on the need for
assistance with activities of daily living rather than on
METs, is associated with signiﬁcantly increased risk of
perioperative morbidity and mortality (135,136).
See Online Data Supplement 8 for additional informa-
tion on exercise capacity and functional capacity.
4.2. Stepwise Approach to Perioperative Cardiac Assessment:
Treatment Algorithm
See Figure 1 for a stepwise approach to perioperative
cardiac assessment.
The GWC developed an algorithmic approach to
perioperative cardiac assessment on the basis of theWeight
2.75
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2.75
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2.70
n groceries? 3.50
urniture? 8.00
4.50
5.25
tennis, or throwing a baseball or football? 6.00
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which is outlined throughout the CPG. The algorithm
incorporates the perspectives of clinicians caring for the
patient to provide informed consent and help guide
perioperative management to minimize risk. It is also
crucial to incorporate the patient’s perspective with
regard to the assessment of the risk of surgery orFIGURE 1 Stepwise Approach to Perioperative Cardiac Assessment for CADalternative therapy and the risk of any GDMT or coro-
nary and valvular interventions before noncardiac sur-
gery. Patients may elect to forgo a surgical intervention
if the risk of perioperative morbidity and mortality is
extremely high; soliciting this information from the
patient before surgery is a key part of shared decision
making.Continued on the next page
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e955. SUPPLEMENTAL PREOPERATIVE EVALUATION
See Table 5 for a summary of recommendations for
supplemental preoperative evaluation.
5.1. The 12-Lead Electrocardiogram: Recommendations
CLASS IIa
1. Preoperative resting 12-lead electrocardiogram (ECG) is
reasonable for patients with known coronary heart disease,
signiﬁcant arrhythmia, peripheral arterial disease, cerebro-
vascular disease, or other signiﬁcant structural heart disease,
except for those undergoing low-risk surgery (137–139).
(Level of Evidence: B)
CLASS IIb
1. Preoperative resting 12-lead ECG may be considered for
asymptomatic patients without known coronary heart disease,
except for those undergoing low-risk surgery (37,138–140).
(Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine preoperative resting 12-lead ECG is not useful for
asymptomatic patients undergoing low-risk surgical pro-
cedures (35,141). (Level of Evidence: B)
In patients with established coronary heart disease, the
resting 12-lead ECG contains prognostic information
relating to short- and long-term morbidity and mortality.
In addition, the preoperative ECG may provide a usefulColors correspond to the Classes of Recommendations in Table 1. Step 1: In patie
urgency of surgery. If an emergency, then determine the clinical risk factors tha
appropriate monitoring and management strategies based on the clinical assess
symptomatic HF, VHD, or arrhythmias, see Sections 2.2, 2.4, and 2.5 for inform
elective, determine if the patient has an ACS. If yes, then refer patient for cardio
NSTEMI and STEMI CPGs (18,20). Step 3: If the patient has risk factors for stab
combined clinical/surgical risk. This estimate can use the American College of S
incorporate the RCRI (131) with an estimation of surgical risk. For example, a pat
with multiple risk factors, would have a low risk of MACE, whereas a patient unde
risk of MACE (Section 3). Step 4: If the patient has a low risk of MACE (<1%), t
(Section 3). Step 5: If the patient is at elevated risk of MACE, then determine fun
the patient has moderate, good, or excellent functional capacity ($4 METs), the
patient has poor (<4 METs) or unknown functional capacity, then the clinician sh
further testing will impact patient decision making (e.g., decision to perform origi
of the test) or perioperative care. If yes, then pharmacological stress testing is
stress testing may be reasonable to perform. If the stress test is abnormal, consi
the abnormal test. The patient can then proceed to surgery with GDMT or consid
surgery (e.g., radiation therapy for cancer) or palliation. If the test is normal, pro
impact decision making or care, then proceed to surgery according to GDMT or
cation for surgery (e.g., radiation therapy for cancer) or palliation. ACS indicates a
artery disease; CPG, clinical practice guideline; DASI, Duke Activity Status Index;
adverse cardiac event; MET, metabolic equivalent; NB, No Beneﬁt; NSQIP, Natio
intervention; RCRI, Revised Cardiac Risk Index; STEMI, ST-elevation myocardial
infarction; and VHD, valvular heart disease.
FIGURE 1 LEGENDbaseline standard against which to measure changes in the
postoperative period. For both reasons, particularly the
latter, the value of the preoperative 12-lead ECG is likely
to increase with the risk of the surgical procedure, partic-
ularly for patients with known coronary heart disease,
arrhythmias, peripheral arterial disease, cerebrovascular
disease, or other signiﬁcant structural heart disease
(137,138).
The prognostic signiﬁcance of numerous electro-
cardiographic abnormalities has been identiﬁed in
observational studies, including arrhythmias (48,142),
pathological Q-waves (37,142), LV hypertrophy (139,142),
ST depressions (137,139,142), QTc interval prolongation
(138,143), and bundle-branch blocks (140,142). However,
there is poor concordance across different observational
studies as to which abnormalities have prognostic sig-
niﬁcance and which do not; a minority of studies found
no prognostic signiﬁcance in the preoperative ECG
(141,144,145). The implications of abnormalities on the
preoperative 12-lead ECG, increase with patient age and
with risk factors for coronary heart disease. However, a
standard age or risk factor cutoff for use of preoperative
electrocardiographic testing has not been deﬁned.
Likewise, the optimal time interval between obtaining a
12-lead ECG and elective surgery is unknown. General
consensus suggests that an interval of 1 to 3 months is
adequate for stable patients.
See Online Data Supplement 9 for additional informa-
tion on the 12-lead ECG.nts scheduled for surgery with risk factors for or known CAD, determine the
t may inﬂuence perioperative management and proceed to surgery with
ment (see Section 2.1 for more information on CAD). (For patients with
ation on evaluation and management.) Step 2: If the surgery is urgent or
logy evaluation and management according to GDMT according to the UA/
le CAD, then estimate the perioperative risk of MACE on the basis of the
urgeons NSQIP risk calculator (http://www.surgicalriskcalculator.com) or
ient undergoing very low-risk surgery (e.g., ophthalmologic surgery), even
rgoing major vascular surgery with few risk factors would have an elevated
hen no further testing is needed, and the patient may proceed to surgery
ctional capacity with an objective measure or scale such as the DASI (133). If
n proceed to surgery without further evaluation (Section 4.1). Step 6: If the
ould consult with the patient and perioperative team to determine whether
nal surgery or willingness to undergo CABG or PCI, depending on the results
appropriate. In those patients with unknown functional capacity, exercise
der coronary angiography and revascularization depending on the extent of
er alternative strategies, such as noninvasive treatment of the indication for
ceed to surgery according to GDMT (Section 5.3). Step 7: If testing will not
consider alternative strategies, such as noninvasive treatment of the indi-
cute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary
GDMT, guideline-directed medical therapy; HF, heart failure; MACE, major
nal Surgical Quality Improvement Program; PCI, percutaneous coronary
infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial
TABLE 5 Summary of Recommendations for Supplemental Preoperative Evaluation
Recommendations COR LOE References
The 12-lead ECG
Preoperative resting 12-lead ECG is reasonable for patients with known coronary heart disease or
other signiﬁcant structural heart disease, except for low-risk surgery
IIa B (137–139)
Preoperative resting 12-lead ECG may be considered for asymptomatic patients, except for
low-risk surgery
IIb B (37,138–140)
Routine preoperative resting 12-lead ECG is not useful for asymptomatic patients undergoing
low-risk surgical procedures
III: No Beneﬁt B (35,141)
Assessment of LV function
It is reasonable for patients with dyspnea of unknown origin to undergo preoperative evaluation
of LV function
IIa C N/A
It is reasonable for patients with HF with worsening dyspnea or other change in clinical status to undergo
preoperative evaluation of LV function
IIa C N/A
Reassessment of LV function in clinically stable patients may be considered IIb C N/A
Routine preoperative evaluation of LV function is not recommended III: No Beneﬁt B (146–148)
Exercise stress testing for myocardial ischemia and functional capacity
For patients with elevated risk and excellent functional capacity, it is reasonable to forgo further
exercise testing and proceed to surgery
IIa B (132,135,136,162,163)
For patients with elevated risk and unknown functional capacity it may be reasonable to perform
exercise testing to assess for functional capacity if it will change management
IIb B (162–164)
For patients with elevated risk and moderate to good functional capacity, it may be reasonable to
forgo further exercise testing and proceed to surgery
IIb B (132,135,136)
For patients with elevated risk and poor or unknown functional capacity it may be reasonable to
perform exercise testing with cardiac imaging to assess for myocardial ischemia
IIb C N/A
Routine screening with noninvasive stress testing is not useful for low-risk noncardiac surgery III: No Beneﬁt B (165,166)
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing may be considered for patients undergoing elevated risk procedures IIb B (171–179)
Noninvasive pharmacological stress testing before noncardiac surgery
It is reasonable for patients at elevated risk for noncardiac surgery with poor functional capacity
to undergo either DSE or MPI if it will change management
IIa B (183–187)
Routine screening with noninvasive stress testing is not useful for low-risk noncardiac surgery III: No Beneﬁt B (165,166)
Preoperative coronary angiography
Routine preoperative coronary angiography is not recommended III: No Beneﬁt C N/A
COR indicates Class of Recommendation; DSE, dobutamine stress echocardiogram; ECG, electrocardiogram; HF, heart failure; LOE, Level of Evidence; LV, left ventricular; MPI,
myocardial perfusion imaging; and N/A, not applicable.
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CLASS IIa
1. It is reasonable for patients with dyspnea of unknown origin
to undergo preoperative evaluation of LV function. (Level of
Evidence: C)
2. It is reasonable for patients with HF with worsening dyspnea
or other change in clinical status to undergo preoperative
evaluation of LV function. (Level of Evidence: C)
CLASS IIb
1. Reassessment of LV function in clinically stable patients with
previously documented LVdysfunctionmay be considered if there
has been no assessment within a year. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine preoperative evaluation of LV function is not
recommended (146–148). (Level of Evidence: B)The relationship between measures of resting LV systolic
function (most commonly LVEF) and perioperative events
has been evaluated in several studies of subjects before
noncardiac surgery (56,58,146–161). These studies
demonstrate an association between reduced LV systolic
function and perioperative complications, particularly
postoperative HF. The association is strongest in patients
at high risk for death. Complication risk is associated with
the degree of systolic dysfunction, with the greatest risk
seen in patients with an LVEF at rest <35%. A preopera-
tively assessed low EF has a low sensitivity but a rela-
tively high speciﬁcity for the prediction of perioperative
cardiac events. However, it has only modest incremental
predictive power over clinical risk factors. The role of
echocardiography in the prediction of risk in patients with
clinical HF is less well studied. A cohort of patients with a
history of HF demonstrated that preoperative LVEF <30%
was associated with an increased risk of perioperative
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operative diastolic function assessment and the risk
of cardiac events (58,59).
In patients who are candidates for potential solid organ
transplantation, a transplantation-speciﬁc CPG has sug-
gested it is appropriate to perform preoperative LV func-
tion assessment by echocardiography (31).
See Online Data Supplement 10 for additional informa-
tion on assessment of LV function.
5.3. Exercise Stress Testing for Myocardial Ischemia and
Functional Capacity: Recommendations
CLASS IIa
1. For patients with elevated risk and excellent (>10 METs)
functional capacity, it is reasonable to forgo further exercise
testing with cardiac imaging and proceed to surgery
(132,135,136,162,163). (Level of Evidence: B)
CLASS IIb
1. For patients with elevated risk and unknown functional
capacity, it may be reasonable to perform exercise testing to
assess for functional capacity if it will change management
(162–164). (Level of Evidence: B)
2. For patients with elevated risk and moderate to good ($4
METs to 10 METs) functional capacity, it may be reasonable
to forgo further exercise testing with cardiac imaging and
proceed to surgery (132,135,136). (Level of Evidence: B)
3. For patients with elevated risk and poor (<4 METs) or un-
known functional capacity, it may be reasonable to perform
exercise testing with cardiac imaging to assess for myo-
cardial ischemia if it will change management. (Level of
Evidence: C)
CLASS III: NO BENEFIT
1. Routine screening with noninvasive stress testing is not
useful for patients at low risk for noncardiac surgery
(165,166). (Level of Evidence: B)
Several studies have examined the role of exercise testing to
identify patients at risk for perioperative complications.
(162–164,167–170) Almost all of these studies were conducted
in patients undergoing peripheral vascular surgery, because
these patients are generally considered to be at the highest
risk (162,164,167–169). Although they were important con-
tributions at the time, the outcomes in most of these studies
are not reﬂective of contemporary perioperative event
rates, nor was the patient management consistent with cur-
rent standards of preventive and perioperative cardiac care.
Furthermore, many used stress protocols that are not
commonly used today, such as non–Bruce protocol treadmill
tests or arm ergometry. However, from the available data,
patients able to achieve approximately 7 METs to 10 METs
have a low risk of perioperative cardiovascular events
(162,164), and those achieving <4 METs to 5 METs have anincreased risk of perioperative cardiovascular events
(163,164). Electrocardiographic changes with exercise are not
as predictive (162–164,169).
The vast majority of data on the impact of inducible
myocardial ischemia on perioperative outcomes are based
on pharmacological stress testing (Sections 5.5.1–5.5.3),
but it seems reasonable that exercise stress echocardiog-
raphy or radionuclide myocardial perfusion imaging (MPI)
would perform similarly to pharmacological stress testing
in patients who are able to exercise adequately.
See Online Data Supplement 11 for additional informa-
tion on exercise stress testing for myocardial ischemia and
functional capacity.
5.4. Cardiopulmonary Exercise Testing: Recommendation
CLASS IIb
1. Cardiopulmonary exercise testing may be considered for
patients undergoing elevated risk procedures in whom func-
tional capacity is unknown (171–179). (Level of Evidence: B)
Cardiopulmonary exercise testing has been studied in
different settings, including before abdominal aortic aneu-
rysm surgery (172–174,180); major abdominal surgery
(including abdominal aortic aneurysm resection) (175–177);
hepatobiliary surgery (178); complex hepatic resection (171);
lung resection (181); and colorectal, bladder, or kidney cancer
surgery (179). These studies varied in patient population,
deﬁnition of perioperative complications, and what was
done with the results of preoperative testing, including
decisions about the appropriateness of proceeding with
surgery. However, a consistent ﬁnding among the studies
was that a low anaerobic threshold was predictive of peri-
operative cardiovascular complications (171,173,177), post-
operative death (172,174,175), or midterm and late death
after surgery (174,179,180). An anaerobic threshold of ap-
proximately 10 mL O2/kg/min was proposed as the optimal
discrimination point, with a range in these studies of 9.9 mL
O2/kg/min to 11 mL O2/kg/min. Although exercise tolerance
can be estimated from instruments such as the DASI (133)
or the incremental shuttle walk test, in 1 study, a signiﬁ-
cant number of patients with poor performance by these
measures had satisfactory peak oxygen consumption and
anaerobic threshold on cardiopulmonary exercise testing
(182). That particular study was not powered to look at
postoperative outcomes.
See Online Data Supplement 12 for additional informa-
tion on cardiopulmonary exercise testing.
5.5. Pharmacological Stress Testing
5.5.1. Noninvasive Pharmacological Stress Testing Before
Noncardiac Surgery: Recommendations
CLASS IIa
1. It is reasonable for patients who are at an elevated risk for
noncardiac surgery and have poor functional capacity
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testing (either dobutamine stress echocardiogram [DSE] or
pharmacological stress MPI) if it will change management
(183–187). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine screening with noninvasive stress testing is not
useful for patients undergoing low-risk noncardiac surgery
(165,166). (Level of Evidence: B)
Pharmacological stress testing with DSE, dipyridamole/
adenosine/regadenoson MPI with thallium-201, and/or
technetium-99m and rubidium-82 can be used in patients
undergoing noncardiac surgery who cannot perform exercise
to detect stress-induced myocardial ischemia and CAD. At
the time of GWC deliberations, publications in this area
conﬁrmed ﬁndings of previous studies rather than providing
new insight as to the optimal noninvasive pharmacol-
ogical preoperative stress testing strategy (31,60,149,165,
183–185,188–204).
Despite the lack of RCTs on the use of preoperative
stress testing, a large number of single-site studies using
either DSE or MPI have shown consistent ﬁndings. These
ﬁndings can be summarized as follows:
 The presence of moderate to large areas of myocardial
ischemia is associated with increased risk of perioper-
ative MI and/or death.
 A normal study for perioperative MI and/or cardiac
death has a very high negative predictive value.
 The presence of an old MI identiﬁed on rest imaging is
of little predictive value for perioperative MI or cardiac
death.
 Several meta-analyses have shown the clinical utility of
pharmacological stress testing in the preoperative
evaluation of patients undergoing noncardiac surgery.
In terms of which pharmacological test to use, there are
no RCTs comparing DSE with pharmacological MPI perio-
peratively. A retrospective, meta-analysis comparing MPI
(thallium imaging) and stress echocardiography in patients
scheduled for elective noncardiac surgery showed that a
moderate to large defect (present in 14% of the population)
detected by either method predicted postoperative cardiac
events. The authors identiﬁed a slight superiority of stress
echocardiography relative to nongated MPI with thallium
in predicting postoperative cardiac events (204). However,
in light of the lack of RCT data, local expertise in per-
forming pharmacological stress testing should be consid-
ered in decisions about which pharmacological stress test
to use.
The recommendations in this CPG do not speciﬁcally
address the preoperative evaluation of patients for kidney
or liver transplantation because the indications for
stress testing may reﬂect both perioperative andlong-term outcomes in this population. The reader is
directed to the AHA/ACC scientiﬁc statement titled “Car-
diac disease evaluation and management among kidney
and liver transplantation candidates” for further recom-
mendations (31).
See Online Data Supplement 13 for additional informa-
tion on noninvasive pharmacological stress testing before
noncardiac surgery.
5.5.2. Radionuclide MPI
The role of MPI in preoperative risk assessment in pa-
tients undergoing noncardiac surgery has been evaluated
in several studies (166,190,193,195,197,199,202–206). The
majority of MPI studies show that moderate to large
reversible perfusion defects, which reﬂect myocardial
ischemia, carry the greatest risk of perioperative cardiac
death or MI. In general, an abnormal MPI test is associated
with very high sensitivity for detecting patients at risk for
perioperative cardiac events. The negative predictive
value of a normal MPI study is high for MI or cardiac
death, although postoperative cardiac events do occur in
this population (204). Most studies have shown that a
ﬁxed perfusion defect, which reﬂects infarcted myocar-
dium, has a low positive predictive value for periopera-
tive cardiac events. However, patients with ﬁxed defects
have shown increased risk for long-term events relative to
patients with a normal MPI test, which likely reﬂects the
fact that they have CAD. Overall, a reversible myocardial
perfusion defect predicts perioperative events, whereas a
ﬁxed perfusion defect predicts long-term cardiac events.
See Online Data Supplement 14 for additional informa-
tion on radionuclide MPI.
5.5.3. Dobutamine Stress Echocardiography
The role of DSE in preoperative risk assessment in pa-
tients undergoing noncardiac surgery has been evaluated
in several studies (186,187,207–220). The deﬁnition of an
abnormal stress echocardiogram in some studies was
restricted to the presence of new wall motion abnormal-
ities with stress, indicative of myocardial ischemia, but in
others also included the presence of akinetic segments at
baseline, indicative of MI. These studies have predomi-
nantly evaluated the role of DSE in patients with an
increased perioperative cardiovascular risk, particularly
those undergoing abdominal aortic or peripheral vascular
surgery. In many studies, the results of the DSE were
available to the managing clinicians and surgeons, which
inﬂuenced perioperative management, including the
preoperative use of diagnostic coronary angiography and
coronary revascularization, and which intensiﬁed medical
management, including beta blockade.
Overall, the data suggest that DSE appears safe and
feasible as part of a preoperative assessment. Safety
and feasibility have been demonstrated speciﬁcally in
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vascular disease, morbid obesity, and severe chronic
obstructive pulmonary disease—populations in which
there had previously been safety concerns (186,187,213,
214,220–222). Overall, a positive test result for DSE was
reported in the range of 5% to 50%. In these studies, with
event rates of 0% to 15%, the ability of a positive test
result to predict an event (nonfatal MI or death) ranged
from 0% to 37%. The negative predictive value is invari-
ably high, typically in the range of 90% to 100%. In
interpreting these values, one must consider the overall
perioperative risk of the population and the potential
results stress imaging had on patient management.
Several large studies reporting the value of DSE in the
prediction of cardiac events during noncardiac surgery
for which Poldermans was the senior author are not
included in the corresponding data supplement table
(223–225); however, regardless of whether the evidence
includes these studies, conclusions are similar.
See Online Data Supplement 15 for additional informa-
tion on DSE.
5.6. Stress Testing—Special Situations
In most ambulatory patients, exercise electrocardio-
graphic testing can provide both an estimate of functional
capacity and detection of myocardial ischemia through
changes in the electrocardiographic and hemodynamic
response. In many settings, an exercise stress ECG is
combined with either echocardiography or MPI. In the
perioperative period, most patients undergo pharmaco-
logical stress testing with either MPI or DSE.
In patients undergoing stress testing with abnormal-
ities on their resting ECG that impair diagnostic inter-
pretation (e.g., left bundle-branch block, LV hypertrophy
with “strain” pattern, digitalis effect), concomitant stress
imaging with echocardiography or MPI may be an
appropriate alternative. In patients with left bundle-
branch block, exercise MPI has an unacceptably low
speciﬁcity because of septal perfusion defects that are not
related to CAD. For these patients, pharmacological stress
MPI, particularly with adenosine, dipyridamole, or rega-
denoson, is suggested over exercise stress imaging.
In patients with indications for stress testing who are
unable to perform adequate exercise, pharmacological
stress testing with either DSE or MPI may be appropriate.
There are insufﬁcient data to support the use of dobut-
amine stress magnetic resonance imaging in preoperative
risk assessment (221).
Intravenous dipyridamole and adenosine should be
avoided in patients with signiﬁcant heart block, bron-
chospasm, critical carotid occlusive disease, or a con-
dition that prevents their being withdrawn from
theophylline preparations or other adenosine antago-
nists; regadenoson has a more favorable side-effectproﬁle and appears safe for use in patients with bron-
chospasm. Dobutamine should be avoided in patients
with serious arrhythmias or severe hypertension. All
stress agents should be avoided in unstable patients. In
patients in whom echocardiographic image quality is
inadequate for wall motion assessment, such as those
with morbid obesity or severe chronic obstructive lung
disease, intravenous echocardiography contrast (187,222)
or alternative methods, such as MPI, may be appro-
priate. An echocardiographic stress test is favored if an
assessment of valvular function or pulmonary hyperten-
sion is clinically important. In many instances, either
exercise stress echocardiography/DSE or MPI may be
appropriate, and local expertise may help dictate the
choice of test.
At the time of publication, evidence did not support the
use of an ambulatory ECG as the only diagnostic test
to refer patients for coronary angiography, but it may
be appropriate in rare circumstances to direct medical
therapy.5.7. Preoperative Coronary Angiography: Recommendation
CLASS III: NO BENEFIT
1. Routine preoperative coronary angiography is not recom-
mended. (Level of Evidence: C)
Data are insufﬁcient to recommend the use of coronary
angiography in all patients (i.e., routine testing), including
for those patients undergoing any speciﬁc elevated-risk
surgery. In general, indications for preoperative coronary
angiography are similar to those identiﬁed for the nonoper-
ative setting. The decreased risk of coronary computerized
tomography angiography compared with invasive angiog-
raphy may encourage its use to determine preoperatively the
presence and extent of CAD. However, any additive value in
decision making of coronary computed tomography angiog-
raphy and calcium scoring is uncertain, given that data
are limited and involve patients undergoing noncardiac
surgery (226).
The recommendations in this CPG do not speciﬁcally
address the preoperative evaluation of patients for kidney
or liver transplantation because the indications for angi-
ography may be different. The reader is directed to the
AHA/ACC scientiﬁc statement titled “Cardiac disease eval-
uation and management among kidney and liver trans-
plantation candidates” for further recommendations (31).
See Online Data Supplement 16 for additional informa-
tion on preoperative coronary angiography.6. PERIOPERATIVE THERAPY
See Table 6 for a summary of recommendations for
perioperative therapy.
yBecause of new evidence, this is a new recommendation since the publication
of the 2011 PCI CPG (26).
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e1006.1. Coronary Revascularization Before Noncardiac Surgery:
Recommendations
CLASS I
1. Revascularization before noncardiac surgery is recommended
in circumstances in which revascularization is indicated
according to existing CPGs (25,26). (Level of Evidence: C)
(See Table A in Appendix 3 for related recommendations.)
CLASS III: NO BENEFIT
1. It is not recommended that routine coronary revascularization
be performed before noncardiac surgery exclusively to reduce
perioperative cardiac events (116). (Level of Evidence: B)
Patients undergoing risk stratiﬁcation before elective non-
cardiac procedures and whose evaluation recommends
CABG surgery should undergo coronary revascularization
before an elevated-risk surgical procedure (227). The cumu-
lative mortality and morbidity risks of both the coronary
revascularization procedure and the noncardiac surgery
should be weighed carefully in light of the individual pa-
tient’s overall health, functional status, and prognosis. The
indications for preoperative surgical coronary revasculariza-
tion are identical to those recommended in the 2011 CABG
CPG and the 2011 PCI CPG and the accumulated data on
which those conclusions were based (25,26) (See Table A in
Appendix 3 for the related recommendations).
The role of preoperative PCI in reducing untoward
perioperative cardiac complications is uncertain given the
available data. Performing PCI before noncardiac surgery
should be limited to 1) patients with left main disease
whose comorbidities preclude bypass surgery without
undue risk and 2) patients with unstable CAD who would
be appropriate candidates for emergency or urgent
revascularization (25,26). Patients with ST-elevation MI or
non–ST-elevation acute coronary syndrome beneﬁt from
early invasive management (26). In such patients, in
whom noncardiac surgery is time sensitive despite an
increased risk in the perioperative period, a strategy
of balloon angioplasty or bare-metal stent (BMS) implan-
tation should be considered.
There are no prospective RCTs supporting coronary
revascularization, either CABG or PCI, before noncardiac
surgery to decrease intraoperative and postoperative
cardiac events. In the largest RCT, CARP (Coronary Artery
Revascularization Prophylaxis), there were no differences
in perioperative and long-term cardiac outcomes with
or without preoperative coronary revascularization by
CABG or PCI in patients with documented CAD, with the
exclusion of those with left main disease, a LVEF <20%,
and severe AS (116). A follow-up analysis reported
improved outcomes in the subset who underwent CABG
compared with those who underwent PCI (228). In an
additional analysis of the database of patients who un-
derwent coronary angiography in both the randomizedand nonrandomized portion of the CARP trial, only the
subset of patients with unprotected left main disease
showed a beneﬁt from preoperative coronary artery
revascularization (229). A second RCT also demonstrated
no beneﬁt from preoperative testing and directed coro-
nary revascularization in patients with 1 to 2 risk factors
for CAD (230), but the conduct of the trial was questioned
at the time of the GWC’s discussions (9).
See Online Data Supplement 17 for additional informa-
tion on coronary revascularization before noncardiac
surgery.
6.1.1. Timing of Elective Noncardiac Surgery in Patients With
Previous PCI: Recommendations
CLASS I
1. Elective noncardiac surgery should be delayed 14 days after
balloon angioplasty (Level of Evidence: C) and 30 days after
BMS implantation (231–233). (Level of Evidence B)
2. Elective noncardiac surgery should optimally be delayed 365
days after drug-eluting stent (DES) implantation (234–237).
(Level of Evidence: B)
CLASS IIa
1. In patients in whom noncardiac surgery is required, a
consensus decision among treating clinicians as to the rela-
tive risks of surgery and discontinuation or continuation of
antiplatelet therapy can be useful. (Level of Evidence: C)
CLASS IIby
1. Elective noncardiac surgery after DES implantation may be
considered after 180 days if the risk of further delay is
greater than the expected risks of ischemia and stent
thrombosis (234,238). (Level of Evidence: B)
CLASS III: HARM
1. Elective noncardiac surgery should not be performed within
30 days after BMS implantation or within 12 months after
DES implantation in patients in whom dual antiplatelet
therapy (DAPT) will need to be discontinued perioperatively
(231–237,239). (Level of Evidence: B)
2. Elective noncardiac surgery should not be performed within
14 days of balloon angioplasty in patients in whom aspirin
will need to be discontinued perioperatively. (Level of
Evidence: C)
Patients who require both PCI and noncardiac surgery merit
special consideration. PCI should not be performed as a
prerequisite in patients who need noncardiac surgery unless
TABLE 6 Summary of Recommendations for Perioperative Therapy
Recommendations COR LOE References
Coronary revascularization before noncardiac surgery
Revascularization before noncardiac surgery is recommended when indicated by existing CPGs I C (25,26)
Coronary revascularization is not recommended before noncardiac surgery exclusively
to reduce perioperative cardiac events
III: No Beneﬁt B (116)
Timing of elective noncardiac surgery in patients with previous PCI
Noncardiac surgery should be delayed after PCI I C: 14 d after
balloon
angioplasty
N/A
B: 30 d
after BMS
implantation
(231–233)
Noncardiac surgery should optimally be delayed 365 d after DES implantation I B (234–237)
A consensus decision as to the relative risks of discontinuation or continuation of antiplatelet
therapy can be useful
IIa C N/A
Elective noncardiac surgery after DES implantation may be considered after 180 d IIb* B (234,238)
Elective noncardiac surgery should not be performed in patients in whom DAPT will need to be
discontinued perioperatively within 30 d after BMS implantation or within 12 mo after DES
implantation
III: Harm B (231–237,239)
Elective noncardiac surgery should not be performed within 14 d of balloon angioplasty in
patients in whom aspirin will need to be discontinued perioperatively
III: Harm C N/A
Perioperative beta-blocker therapy
Continue beta blockers in patients who are on beta blockers chronically I B SR† (242–248)
Guide management of beta blockers after surgery by clinical circumstances IIa B SR† (241,248,251)
In patients with intermediate- or high-risk preoperative tests, it may be reasonable to
begin beta blockers
IIb C SR† (225)
In patients with $3 RCRI factors, it may be reasonable to begin beta blockers before surgery IIb B SR† (248)
Initiating beta blockers in the perioperative setting as an approach to reduce perioperative risk is
of uncertain beneﬁt in those with a long-term indication but no other RCRI risk factors
IIb B SR† (242,248,257)
It may be reasonable to begin perioperative beta blockers long enough in advance to assess safety
and tolerability, preferably >1 d before surgery
IIb B SR† (241,258–260)
Beta-blocker therapy should not be started on the d of surgery III: Harm B SR† (241)
Perioperative statin therapy
Continue statins in patients currently taking statins I B (283–286)
Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery IIa B (287)
Perioperative initiation of statins may be considered in patients with a clinical risk factor
who are undergoing elevated-risk procedures
IIb C N/A
Alpha-2 agonists
Alpha-2 agonists are not recommended for prevention of cardiac events III: No Beneﬁt B (291–295)
ACE inhibitors
Continuation of ACE inhibitors or ARBs is reasonable perioperatively IIa B (300,301)
If ACE inhibitors or ARBs are held before surgery, it is reasonable to restart as soon as
clinically feasible postoperatively
IIa C N/A
Antiplatelet agents
Continue DAPT in patients undergoing urgent noncardiac surgery during the ﬁrst 4 to 6 wk after
BMS or DES implantation, unless the risk of bleeding outweighs the beneﬁt of stent
thrombosis prevention
I C N/A
In patients with stents undergoing surgery that requires discontinuation P2Y12 inhibitors, continue
aspirin and restart the P2Y12 platelet receptor–inhibitor as soon as possible after surgery
I C N/A
Management of perioperative antiplatelet therapy should be determined by consensus of treating
clinicians and the patient
I C N/A
In patients undergoing nonemergency/nonurgent noncardiac surgery without prior coronary
stenting, it may be reasonable to continue aspirin when the risk of increased cardiac events
outweighs the risk of increased bleeding
IIb B (298,306)
Continued on the next page
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TABLE 6 Continued
Recommendations COR LOE References
Initiation or continuation of aspirin is not beneﬁcial in patients undergoing elective noncardiac
noncarotid surgery who have not had previous coronary stenting
III: No Beneﬁt B (298)
C: If risk of
ischemic
events
outweighs
risk of
surgical
bleeding
N/A
Perioperative management of patients with CIEDs
Patients with ICDs should be on a cardiac monitor continuously during the entire period of
inactivation, and external deﬁbrillation equipment should be available. Ensure that ICDs are
reprogrammed to active therapy
I C (336)
*Because of new evidence, this is a new recommendation since the publication of the 2011 PCI CPG (26).
†These recommendations have been designated with a SR to emphasize the rigor of support from the ERC’s systematic review.
ACE indicates angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; BMS, bare-metal stent; CIED, cardiovascular implantable electronic device; COR, Class of
Recommendation; CPG, clinical practice guideline; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ERC, Evidence Review Committee; ICD, implantable cardioverter-
deﬁbrillator; LOE, Level of Evidence; N/A, not applicable; PCI, percutaneous coronary intervention; RCRI, Revised Cardiac Risk Index; and SR, systematic review.
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(e.g., left main disease), unstable angina, MI, or life-
threatening arrhythmias due to active ischemia amenable
to PCI. If PCI is necessary, then the urgency of the noncardiac
surgery and the risk of bleeding and ischemic events,
including stent thrombosis, associated with the surgery in a
patient taking DAPT need to be considered (see Section 6.2.6
for more information on antiplatelet management). If there is
little risk of bleeding or if the noncardiac surgery can be
delayed $12 months, then PCI with DES and prolonged
aspirin and P2Y12 platelet receptor–inhibitor therapy is an
option. Some data suggest that in newer-generation DESs,
the risk of stent thrombosis is stabilized by 6 months after
DES implantation and that noncardiac surgery after 6 months
may be possible without increased risk (234,238). If the
elective noncardiac surgery is likely to occur within 1 to 12
months, then a strategy of BMS and 4 to 6 weeks of aspirin
and P2Y12 platelet receptor–inhibitor therapy with continua-
tion of aspirin perioperatively may be an appropriate option.
Although the risk of restenosis is higher with BMS than with
DES, restenotic lesions are usually not life threatening, even
though they may present as an acute coronary syndrome,
and they can usually be dealt with by repeat PCI if necessary.
If the noncardiac surgery is time sensitive (within 2 to 6
weeks) or the risk of bleeding is high, then consideration
should be given to balloon angioplasty with provisional BMS
implantation. If the noncardiac surgery is urgent or an
emergency, then the risks of ischemia and bleeding, and the
long-term beneﬁt of coronary revascularization must be
weighed. If coronary revascularization is absolutely neces-
sary, CABG combined with the noncardiac surgery may be
considered.
See Online Data Supplement 18 for additional informa-
tion on strategy of percutaneous revascularization in
patients needing elective noncardiac surgery.6.2. Perioperative Medical Therapy
6.2.1. Perioperative Beta-Blocker Therapy: Recommendations
See the ERC systematic review report, “Perioperative beta
blockade in noncardiac surgery: a systematic review for
the 2014 ACC/AHA guideline on perioperative cardiovas-
cular evaluation and management of patients undergoing
noncardiac surgery” for the complete evidence review on
perioperative beta-blocker therapy (8), and see Online
Data Supplement 19 for more information about beta
blockers. The tables in Online Data Supplement 19 were
reproduced directly from the ERC’s systematic review for
your convenience. These recommendations have been
designated with an SR to emphasize the rigor of support
from the ERC’s systematic review.
As noted in the Scope of this CPG (Section 1.4), the
recommendations in Section 6.2.1 are based on a sepa-
rately commissioned review of the available evidence,
the results of which were used to frame our decision
making. Full details are provided in the ERC’s systematic
review report (8) and data supplements. However, 3
key ﬁndings were powerful inﬂuences on this CPG’s
recommendations:
1. The systematic review suggests that preoperative use
of beta blockers was associated with a reduction in
cardiac events in the studies examined, but few data
support the effectiveness of preoperative administra-
tion of beta blockers to reduce risk of surgical death.
2. Consistent and clear associations exist between beta-
blocker administration and adverse outcomes, such as
bradycardia and stroke.
3. These ﬁndings were quite consistent even when the
DECREASE studies (230,240) in question or the
POISE (Perioperative Ischemic Evaluation) (241) were
excluded. Stated alternatively, exclusion of these
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beneﬁt.
CLASS I
1. Beta blockers should be continued in patients undergoing
surgery who have been on beta blockers chronically
(242–248). (Level of Evidence: B) SR
If well tolerated, continuing beta blockers in patients who are
currently receiving them for longitudinal reasons, particu-
larly when longitudinal treatment is provided according to
GDMT, such as for MI, is recommended (See Table B in
Appendix 3 for applicable recommendations from the 2011
secondary prevention CPG) (249). Multiple observational
studies support the beneﬁts of continuing beta blockers in
patients who are undergoing surgery and who are on these
agents for longitudinal indications (242–248). However,
these studies vary in their robustness in terms of their ability
to deal with confounding due to the indications for beta
blockade or ability to discern whether the reasons for dis-
continuation are in themselves associated with higher risk
(independent of beta-blocker discontinuation), which led to
the Level of Evidence B determination. This recommenda-
tion is consistent with the Surgical Care Improvement Project
National Measures (CARD-2) as of November 2013 (250).
CLASS IIa
1. It is reasonable for the management of beta blockers after
surgery to be guided by clinical circumstances, independent
of when the agent was started (241,248,251). (Level of
Evidence: B) SR
This recommendation requires active management of pa-
tients on beta blockers during and after surgery. Particular
attention should be paid to the need to modify or tempo-
rarily discontinue beta blockers as clinical circumstances
(e.g., hypotension, bradycardia (252), bleeding) (251) dictate.
Although clinical judgment will remain a mainstay of this
approach, evidence suggests that implementation of and
adherence to local practice guidelines can play a role in
achieving this recommendation (253).
CLASS IIb
1. In patients with intermediate- or high-risk myocardial
ischemia noted in preoperative risk stratiﬁcation tests, it may
be reasonable to begin perioperative beta blockers (225).
(Level of Evidence: C) SR
The risks and beneﬁts of perioperative beta blocker use
appear to be favorable in patients who have intermediate- or
high-risk myocardial ischemia noted on preoperative stress
testing (225,254). The decision to begin beta blockers should
be inﬂuenced by whether a patient is at risk for stroke
(46,255,256) and whether the patient has other relative
contraindications (such as uncompensated HF).CLASS IIb
2. In patients with 3 or more RCRI risk factors (e.g., diabetes
mellitus, HF, CAD, renal insufﬁciency, cerebrovascular acci-
dent), it may be reasonable to begin beta blockers before
surgery (248). (Level of Evidence: B) SR
Observational data suggest that patients appear to beneﬁt
from use of beta blockers in the perioperative setting if they
have $3 RCRI risk factors. In the absence of multiple risk
factors, it is unclear whether preoperative administration is
safe or effective; again, it is important to gauge the risk
related to perioperative stroke or contraindications in
choosing to begin beta blockers.
CLASS IIb
3. In patients with a compelling long-term indication for beta-
blocker therapy but no other RCRI risk factors, initiating
beta blockers in the perioperative setting as an approach
to reduce perioperative risk is of uncertain beneﬁt
(242,248,257). (Level of Evidence: B) SR
Although beta blockers improve long-term outcomes when
used in patients according to GDMT, it is unclear whether
beginning beta blockers before surgery is efﬁcacious or safe if
a long-term indication is not accompanied by additional
RCRI criteria. Rather, a preferable approach might be to
ensure beta blockers are initiated as soon as feasible after
the surgical procedure.
CLASS IIb
4. In patients in whom beta-blocker therapy is initiated, it may
be reasonable to begin perioperative beta blockers long
enough in advance to assess safety and tolerability, prefer-
ably more than 1 day before surgery (241,258–260). (Level
of Evidence: B) SR
It may be reasonable to begin beta blockers long enough in
advance of the operative date that clinical effectiveness
and tolerability can be assessed (241,258–260).
Beginning beta blockers #1 day before surgery is at a
minimum ineffective and may in fact be harmful
(8,241,248,261). Starting the medication 2 to 7 days before
surgery may be preferred, but few data support the need
to start beta blockers >30 days beforehand (258–260). It is
important to note that even in studies that included
preoperative dose titration as an element of their algo-
rithm, patients’ drug doses rarely changed after an initial
dose was chosen (254,262). In addition, the data sup-
porting “tight” heart rate control is weak (262), suggesting
that clinical assessments for tolerability are a key element
of preoperative strategies (258–260).CLASS III: HARM
1. Beta-blocker therapy should not be started on the day of
surgery (241). (Level of Evidence: B) SR
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blockers on the day of surgery in beta–blocker-naïve patients
(241), particularly at high initial doses, in long-acting form,
and if there no plans for dose titration or monitoring for
adverse events.
6.2.1.1. Evidence on Efﬁcacy of Beta-Blocker Therapy
Initial interest in using beta blockers to prevent post-
operative cardiac complications was supported by a small
number of RCTs and reviews (225,254,263,264). Periop-
erative beta blockade was quickly adopted because the
potential beneﬁt of perioperative beta blockers was large
(265) in the absence of other therapies, initial RCTs
did not suggest adverse effects, and the effects of beta
blockers in surgical patients were consistent with effects
in patients with MI (e.g., reducing mortality rate from
coronary ischemia).
However, these initial data were derived primarily
from small trials, with minimum power, of highly
screened patient populations undergoing speciﬁc pro-
cedures (e.g., vascular surgery) and using agents (e.g.,
intravenous atenolol, oral bisoprolol) not widely avail-
able in the United States. Limitations of initial studies
provided the rationale for studies that followed
(241,266), of which 3 showed no cardiac outcome or
mortality difference between beta–blocker-treated and
-untreated patients (257,267,268). Additional informa-
tion was provided by a meta-analysis of all published
studies that suggested potential harm as well as a lower
protective effect (269); a robust observational study also
suggested an association between use of beta blockers
in low-risk patients and higher surgical mortality
rate (242).
Publication of POISE, a multicenter study of adequate
size and scope to address sample size, generalizability,
and limitations of previous studies, added further
complexity to the evidence base by suggesting that use
of beta blockers reduced risks for cardiac events (e.g.,
ischemia, AF, need for coronary interventions) but pro-
duced a higher overall risk—largely related to stroke and
higher rate of death resulting from noncardiac complica-
tions (241). However, POISE was criticized for its use of a
high dose of long-acting beta blocker and for initiation of
the dose immediately before noncardiac surgery. In fact, a
lower starting dose was used in the 3 studies that saw
both no harm and no beneﬁt (257,267,270). Moreover,
POISE did not include a titration protocol before or after
surgery.
The evidence to this point was summarized in a series
of meta-analyses suggesting a mixed picture of the safety
and efﬁcacy of beta blockers in the perioperative setting
(269,271–273). These evidence summaries were relatively
consistent in showing that use of perioperative beta
blockers could reduce perioperative cardiac risk but thatthey had signiﬁcant deleterious associations with brady-
cardia, stroke, and hypotension.
Adding further complexity to the perioperative beta-
blocker picture, concern was expressed by Erasmus Uni-
versity about the scientiﬁc integrity of studies led by
Poldermans (9); see Section 1.4 for further discussion.
For transparency, we included the nonretracted publica-
tions in the text of this document if they were relevant
to the topic. However, the nonretracted publications
were not used as evidence to support the recommen-
dations and were not included in the corresponding
data supplement.
6.2.1.2. Titration of Beta Blockers
There are limited trial data on whether or how to titrate
beta blockers in the perioperative setting or whether this
approach is more efﬁcacious than ﬁxed-dose regimens.
Although several studies (254,263) included dose titration
to heart rate goal in their protocol, and separate studies
suggested that titration is important to achieving appro-
priate anti-ischemic effects (274), it appears that many
patients in the original trials remained on their starting
medication dose at the time of surgery, even if on a
research protocol.
Studies that titrated beta blockers, many of which are
now under question, also tended to begin therapy >1 day
before surgery, making it difﬁcult to discern whether dose
titration or preoperative timing was more important to
producing any potential beneﬁts of beta blockade.
Several studies have evaluated the intraclass differ-
ences in beta blockers (according to duration of action and
beta-1 selectivity) (261,275–278), but few comparative tri-
als exist at the time of publication, and it is difﬁcult to
make broad recommendations on the basis of evidence
available at this time. Moreover, some intraclass differ-
ences may be inﬂuenced more by differences in beta-
adrenoceptor type than by the medication itself (279).
However, data from POISE suggest that initiating long-
acting beta blockers on the day of surgery may not be a
preferable approach.
6.2.1.3. Withdrawal of Beta Blockers
Although few studies describe risks of withdrawing beta
blockers in the perioperative time period (243,246),
longstanding evidence from other settings suggests that
abrupt withdrawal of long-term beta blockers is harmful
(280–282), providing the major rationale for the ACC/AHA
Class I recommendation. There are fewer data to describe
whether short-term (1 to 2 days) perioperative use of beta
blockers, followed by rapid discontinuation, is harmful.
6.2.1.4 Risks and Caveats
The evidence for perioperative beta blockers—even
excluding the DECREASE studies under question and
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operative cardiac events. However, this beneﬁt is offset
by a higher relative risk for perioperative strokes and
uncertain mortality beneﬁt or risk (242,248,254). More-
over, the time horizon for beneﬁt in some cases may be
farther in the future than the time horizon for adverse
effects of the drugs.
In practice, the risk–beneﬁt analysis of perioperative
beta blockers should also take into account the frequency
and severity of the events the therapy may prevent or
produce. That is, although stroke is a highly morbid
condition, it tends to be far less common than MACE.
There may be situations in which the risk of perioperative
stroke is lower, but the concern for cardiac events is
elevated; in these situations, beta blocker use may have
beneﬁt, though little direct evidence exists to guide
clinical decision making in speciﬁc scenarios.
6.2.2. Perioperative Statin Therapy: Recommendations
CLASS I
1. Statins should be continued in patients currently taking
statins and scheduled for noncardiac surgery (283–286).
(Level of Evidence: B)
CLASS IIa
1. Perioperative initiation of statin use is reasonable in patients
undergoing vascular surgery (287). (Level of Evidence: B)
CLASS IIb
1. Perioperative initiation of statins may be considered in pa-
tients with clinical indications according to GDMT who are
undergoing elevated-risk procedures. (Level of Evidence: C)
Lipid lowering with statin agents is highly effective for pri-
mary and secondary prevention of cardiac events (288). Data
from statin trials are now robust enough to allow the GWC to
directly answer the critical questions of what works and in
whom without estimating cardiovascular risk. The effec-
tiveness of this class of agents in reducing cardiovascular
events in high-risk patients has suggested that they may
improve perioperative cardiovascular outcomes. A placebo-
controlled randomized trial followed patients on atorvasta-
tin for 6 months (50 patients on atorvastatin and 50 patients
on placebo) who were undergoing vascular surgery and
found a signiﬁcant decrease in MACE in the treated group
(287). In a Cochrane analysis, pooled results from 3 studies,
with a total of 178 participants, were evaluated (289). In the
statin group, 7 of 105 (6.7%) participants died within 30 days
of surgery, as did 10 of 73 (13.7%) participants in the control
group. However, all deaths occurred in a single study pop-
ulation, and estimates were therefore derived from only 1
study. Two additional RCTs from Poldermans also evaluated
the efﬁcacy of ﬂuvastatin compared with placebo and
demonstrated a signiﬁcant reduction in MACE in patients athigh risk, with a trend toward improvement in patients at
intermediate risk (240,290).
Most of the data on the impact of statin use in the
perioperative period comes from observational trials. The
largest observational trial used data from hospital
administrative databases (283). Patients who received
statins had a lower crude mortality rate and a lower
mortality rate when propensity matched. An administra-
tive database from 4 Canadian provinces was used to
evaluate the relationship between statin use and out-
comes in patients undergoing carotid endarterectomy for
symptomatic carotid disease (284); this study found an
inverse correlation between statin use and in-hospital
mortality, stroke or death, or cardiovascular outcomes.
A retrospective cohort of 752 patients undergoing
intermediate-risk, noncardiac, nonvascular surgery was
evaluated for all-cause mortality rate (285). Compared
with nonusers, patients on statin therapy had a 5-fold
reduced risk of 30-day all-cause death. Another observa-
tional trial of 577 patients revealed that patients under-
going noncardiac vascular surgery treated with statins
had a 57% lower chance of having perioperative MI or
death at 2-year follow-up, after controlling for other var-
iables (286).
The accumulated evidence to date suggests a protec-
tive effect of perioperative statin use on cardiac compli-
cations during noncardiac surgery. RCTs are limited in
patient numbers and types of noncardiac surgery. The
time of initiation of statin therapy and the duration of
therapy are often unclear in the observational trials. The
mechanism of beneﬁt of statin therapy prescribed peri-
operatively to lower cardiac events is unclear and may be
related to pleiotropic as well as cholesterol-lowering ef-
fects. In patients meeting indications for statin therapy,
starting statin therapy perioperatively may also be an
opportunity to impact long-term health (288).
See Online Data Supplement 20 for additional informa-
tion on perioperative statin therapy.
6.2.3. Alpha-2 Agonists: Recommendation
CLASS III: NO BENEFIT
1. Alpha-2 agonists for prevention of cardiac events are not
recommended in patients who are undergoing noncardiac
surgery (291–295). (Level of Evidence: B)
Several studies examined the role of alpha-agonists (cloni-
dine and mivazerol) for perioperative cardiac protection
(291,293,294,296).
In a meta-analysis of perioperative alpha-2 agonist
administration through 2008, comprising 31 trials
enrolling 4578 patients, alpha-2 agonists overall reduced
death and myocardial ischemia (295). The most notable
effects were with vascular surgery. Importantly, sudden
discontinuation of long-term alpha-agonist treatment
Fleisher et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
ACC/AHA Perioperative Clinical Practice Guideline D E C E M B E R 9 , 2 0 1 4 : e 7 7 – 1 3 7
e106can result in hypertension, headache, agitation, and
tremor.
A 2004 prospective, double-blinded, clinical trial on
patients with or at risk for CAD investigated whether
prophylactic clonidine reduced perioperative myocardial
ischemia and long-term death in patients undergoing
noncardiac surgery (297). Patients were randomized to
clonidine (n¼125) or placebo (n¼65). Prophylactic cloni-
dine administered perioperatively signiﬁcantly reduced
myocardial ischemia during the intraoperative and post-
operative period (clonidine: 18 of 125 patients or 14%;
placebo: 20 of 65 patients or 31%; p¼0.01). Moreover,
administration of clonidine had minimal hemodynamic
effects and reduced postoperative mortality rate for up to
2 years (clonidine: 19 of 125 patients or 15%; placebo: 19 of
65 patients or 29%; relative risk: 0.43; 95% CI: 0.21 to
0.89; p¼0.035).
POISE-2 enrolled patients in a large multicenter, in-
ternational, blinded, 2  2 factorial RCT of acetyl-salicylic
acid and clonidine (298). The primary objective was to
determine the impact of clonidine compared with pla-
cebo and acetyl-salicylic acid compared with placebo on
the 30-day risk of all-cause death or nonfatal MI in pa-
tients with or at risk of atherosclerotic disease who were
undergoing noncardiac surgery. Patients in the POISE-2
trial were randomly assigned to 1 of 4 groups: acetyl-
salicylic acid and clonidine together, acetyl-salicylic
acid and clonidine placebo, an acetyl-salicylic acid pla-
cebo and clonidine, or an acetyl-salicylic acid placebo
and a clonidine placebo. Clonidine did not reduce the
rate of death or nonfatal MI. Clonidine did increase the
rate of nonfatal cardiac arrest and clinically important
hypotension.
See Online Data Supplement 21 for additional informa-
tion on alpha-2 agonists.
6.2.4. Perioperative Calcium Channel Blockers
A 2003 meta-analysis of perioperative calcium channel
blockers in noncardiac surgery identiﬁed 11 studies
involving 1007 patients (299). Calcium channel blockers
signiﬁcantly reduced ischemia (relative risk: 0.49; 95% CI:
0.30 to 0.80; p¼0.004) and supraventricular tachycardia
(relative risk: 0.52; 95% CI: 0.37 to 0.72; p<0.0001). Cal-
cium channel blockers were associated with trends to-
ward reduced death and MI. In post hoc analyses, calcium
channel blockers signiﬁcantly reduced death/MI (relative
risk: 0.35; 95% CI: 0.15 to 0.86; p¼0.02). The majority of
these beneﬁts were attributable to diltiazem. Dihy-
dropyridines and verapamil did not decrease the inci-
dence of myocardial ischemia, although verapamil
decreased the incidence of supraventricular tachycardia.
A large-scale trial is needed to deﬁne the value of these
agents. Of note, calcium blockers with substantial nega-
tive inotropic effects, such as diltiazem and verapamil,may precipitate or worsen HF in patients with depressed
EF and clinical HF.
See Online Data Supplement 22 for additional informa-
tion on perioperative calcium channel blockers.
6.2.5. Angiotensin-Converting Enzyme Inhibitors:
Recommendations
CLASS IIa
1. Continuation of angiotensin-converting enzyme (ACE) in-
hibitors or angiotensin-receptor blockers (ARBs) perioper-
atively is reasonable (300,301). (Level of Evidence: B)
2. If ACE inhibitors or ARBs are held before surgery, it is
reasonable to restart as soon as clinically feasible post-
operatively. (Level of Evidence: C)
ACE inhibitors are among the most prescribed drugs in the
United States, but data on their potential risk and beneﬁt in
the perioperative setting is limited to observational analysis.
One large retrospective study evaluated 79 228 patients
(9905 patients on ACE inhibitors [13%] and 66620 patients
not on ACE inhibitors [87%]) who had noncardiac surgery
(300). Among a matched, nested cohort in this study, intra-
operative ACE inhibitor users had more frequent transient
intraoperative hypotension but no difference in other out-
comes. A meta-analysis of available trials similarly demon-
strated hypotension in 50% of patients taking ACE inhibitors
or ARBs on the day of surgery but no change in important
cardiovascular outcomes (i.e., death, MI, stroke, kidney
failure) (301). One study evaluated the beneﬁts of the addi-
tion of aspirin to beta blockers and statins, with or without
ACE inhibitors, for postoperative outcome in high-risk
consecutive patients undergoing major vascular surgery
(302). The combination of aspirin, beta blockers, and statin
therapy was associated with better 30-day and 12-month risk
reduction for MI, stroke, and death than any of the 3 medi-
cations independently. The addition of an ACE inhibitor to
the 3 medications did not demonstrate additional risk-
reduction beneﬁts. There is similarly limited evidence on
the impact of discontinuing ACE inhibitors before noncardiac
surgery (303,304). In these and other small trials, no harmwas
demonstrated with holding ACE inhibitors and ARBs before
surgery (303,304), but all studies were underpowered and did
not target any particular clinical group. Consequently, there
are few data to direct clinicians about whether speciﬁc sur-
gery types or patient subgroups are most likely to beneﬁt
from holding ACE inhibitors in the perioperative time period.
Although there is similarly sparse evidence to support
the degree of harm represented by inappropriate dis-
continuation of ACE inhibitors after surgery (e.g., ACE
inhibitors held but not restarted), there is reasonable ev-
idence from nonsurgical settings to support worse out-
comes in patients whose ACE inhibitors are discontinued
inappropriately. Maintaining continuity of ACE inhibitors
in the setting of treatment for HF or hypertension is
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ARBs are sparse, but treating such drugs as equivalent to
ACE inhibitors is reasonable.
See Online Data Supplement 23 for additional informa-
tion on ACE inhibitors.
6.2.6. Antiplatelet Agents: Recommendations
Please see Figure 2 for an algorithm for antiplatelet man-
agement in patients with PCI and noncardiac surgery.
CLASS I
1. In patients undergoing urgent noncardiac surgery during the
ﬁrst 4 to 6 weeks after BMS or DES implantation, DAPT
should be continued unless the relative risk of bleeding
outweighs the beneﬁt of the prevention of stent thrombosis.
(Level of Evidence: C)
2. In patients who have received coronary stents and must
undergo surgical procedures that mandate the discontinua-
tion of P2Y12 platelet receptor–inhibitor therapy, it is rec-
ommended that aspirin be continued if possible and the
P2Y12 platelet receptor–inhibitor be restarted as soon as
possible after surgery. (Level of Evidence: C)
3. Management of the perioperative antiplatelet therapy
should be determined by a consensus of the surgeon, anes-
thesiologist, cardiologist, and patient, who should weigh the
relative risk of bleeding with that of stent thrombosis.
(Level of Evidence: C)
CLASS IIb
1. In patients undergoing nonemergency/nonurgent noncardiac
surgery who have not had previous coronary stenting, it may
be reasonable to continue aspirin when the risk of potential
increased cardiac events outweighs the risk of increased
bleeding (298,306). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Initiation or continuation of aspirin is not beneﬁcial in pa-
tients undergoing elective noncardiac noncarotid surgery
who have not had previous coronary stenting (298) (Level of
Evidence: B), unless the risk of ischemic events outweighs
the risk of surgical bleeding. (Level of Evidence: C)
The risk of stent thrombosis in the perioperative period for
both BMS and DES is highest in the ﬁrst 4 to 6 weeks after
stent implantation (231–239,307–309). Discontinuation of
DAPT, particularly in this early period, is a strong risk factor
for stent thrombosis (310,311). Should urgent or emergency
noncardiac surgery be required, a decision to continue
aspirin or DAPT should be individualized, with the risk
weighed against the beneﬁts of continuing therapy.
The risk of DES thrombosis during noncardiac surgery
more than 4 to 6 weeks after stent implantation is low but
is higher than in the absence of surgery, although the
relative increased risk varies from study to study. Thisrisk decreases with time and may be at a stable level by 6
months after DES implantation (234,238). The value of
continuing aspirin alone or DAPT to prevent stent
thrombosis or other ischemic events during noncardiac
surgery is uncertain, given the lack of prospective trials.
The risk of bleeding is likely higher with DAPT than with
aspirin alone or no antiplatelet therapy, but the magni-
tude of the increase is uncertain (231,232,307–309,312). As
such, use of DAPT or aspirin alone should be individual-
ized on the basis of the considered potential beneﬁts and
risks, albeit in the absence of secure data. An algorithm
for DAPT use based on expert opinion is suggested in
Figure 2. There is no convincing evidence that warfarin,
antithrombotics, cangrelor, or glycoprotein IIb/IIIa agents
will reduce the risk of stent thrombosis after discontinu-
ation of oral antiplatelet agents.
The value of aspirin in nonstented patients in pre-
venting ischemic complications is uncertain. Observa-
tional data suggest that preoperative withdrawal of
aspirin increases thrombotic complications (306); the PEP
(Pulmonary Embolism Prevention) trial, which random-
ized 13 356 patients undergoing hip surgery to 160 mg
aspirin or placebo, did not show beneﬁt of aspirin (313).
The POISE-2 trial randomized 10 010 patients who were
undergoing noncardiac surgery and were at risk for
vascular complications to aspirin 200 mg or placebo.
Aspirin did not have a protective effect for MACE or death
in patients either continuing aspirin or starting aspirin
during the perioperative period (298). Aspirin use was
associated with an increased risk of major bleeding. In the
POISE-2 trial, aspirin was stopped at least 3 days (but
usually 7 days) preoperatively. Patients within 6 weeks of
placement of a BMS or within 1 year of placement of a DES
were excluded from the trial, and the number of stented
patients outside these time intervals was too small to
make ﬁrm conclusions as to the risk–beneﬁt ratio. Addi-
tionally, only 23% of the study population had known
prior CAD, and the population excluded patients under-
going carotid endarterectomy surgery. Thus, continuation
may still be reasonable in patients with high-risk CAD or
cerebrovascular disease, where the risks of potential
increased cardiovascular events outweigh the risks of
increased bleeding.
See Online Data Supplement 24 for additional informa-
tion on antiplatelet agents.
6.2.7. Anticoagulants
Use of therapeutic or full-dose anticoagulants (as
opposed to the lower-dose anticoagulation often used for
prevention of deep venous thrombosis) is generally
discouraged because of their harmful effect on the ability
to control and contain surgical blood loss. This section
refers to the vitamin K antagonists and novel oral
anticoagulant agents but excludes discussion of the
FIGURE 2 Algorithm for Antiplatelet Management in Patients With PCI and Noncardiac Surgery
Colors correspond to the Classes of Recommendations in Table 1. *Assuming patient is currently on DAPT. ASA indicates aspirin; ASAP, as soon as possible;
BMS, bare-metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; and PCI, percutaneous coronary intervention.
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inhibitors and direct thrombin inhibitors are examples of
alternative anticoagulants now available for oral admin-
istration. Vitamin K antagonists (warfarin) are prescribed
for stroke prevention in patients with AF, for prevention
of thrombotic and thromboembolic complications in pa-
tients with prosthetic valves, and in patients requiringdeep venous thrombosis prophylaxis and treatment.
Factor Xa inhibitors are prescribed for prevention of
stroke in the management of AF. Factor Xa inhibitors are
not recommended for long-term anticoagulation of
prosthetic valves because of an increased risk of throm-
bosis when compared with warfarin. The role of antico-
agulants other than platelet inhibitors in the secondary
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elucidated.
The risks of bleeding for any surgical procedure must
be weighed against the beneﬁt of remaining on antico-
agulants on a case-by-case basis. In some instances in
which there is minimal to no risk of bleeding, such as
cataract surgery or minor dermatologic procedures, it may
be reasonable to continue anticoagulation perioper-
atively. Two published CPGs address the management of
perioperative anticoagulation in patients with prosthetic
valves and patients with AF (14,15). Although research
with newer agents (e.g., prothrombin complex concen-
trates for reversal of direct factor Xa inhibitor effect) is
ongoing, the novel oral anticoagulant agents do not
appear to be acutely reversible. Patients with prosthetic
valves taking vitamin K antagonists may require bridging
therapy with either unfractionated heparin or low-
molecular-weight heparin, depending on the location of
the prosthetic valve and associated risk factors for
thrombotic and thromboembolic events. For patients with
a mechanical mitral valve, regardless of the absence of
additional risk factors for thromboembolism, or patients
with an aortic valve and $1 additional risk factor (such as
AF, previous thromboembolism, LV dysfunction, hyper-
coagulable condition, or an older-generation prosthetic
aortic valve), bridging anticoagulation may be appropriate
when interruption of anticoagulation for perioperative
procedures is required and control of hemostasis is
essential (15). For patients requiring urgent reversal of
vitamin K antagonists, vitamin K and fresh frozen plasma
or the newer prothrombin complex concentrates are op-
tions; however, vitamin K is not routinely recommended
for reversal because the effect is not immediate and
the administration of vitamin K can signiﬁcantly delay
the return to a therapeutic level of anticoagulation once
vitamin K antagonists have been restarted.
Factor Xa inhibitors do not have a reversible agent
available at this time. For patients with AF and normal
renal function undergoing elective procedures during
which hemostatic control is essential, such as major sur-
gery, spine surgery, and epidural catheterization, discon-
tinuation of anticoagulants for $48 hours is suggested.
Monitoring activated partial thromboplastin time for dabi-
gatran and prothrombin time for apixaban and rivaroxaban
may be helpful; a level consistent with control levels sug-
gests a low serum concentration of the anticoagulant (14).
There have been no studies on the beneﬁt of antico-
agulants on the prevention of perioperative myocardial
ischemia or MI.
6.3. Management of Postoperative Arrhythmias and
Conduction Disorders
AF and atrial ﬂutter are the most common sustained ar-
rhythmias that occur in the postoperative setting.However, clinicians must differentiate between atrial
ﬂutter, which is common in the postoperative setting
(especially with underlying structural heart disease), and
other supraventricular tachycardias that may respond to
vagal maneuvers or nodal agents. The incidence of post-
operative AF after noncardiac surgery varies widely in the
literature, ranging from 0.37% in 1 large population-based
study in noncardiothoracic surgery to 30% after major
noncardiac thoracic surgery, such as esophagectomy and
pneumonectomy (314–324). Peak incidence occurs 1 to 3
days postoperatively and is positively correlated with
patient age, preoperative heart rate, and male sex
(315,317,322,325). Treatment of postoperative AF is similar
to that for other forms of new-onset AF, except that the
potential beneﬁt of anticoagulation needs to be balanced
against the risk of postoperative bleeding.
Ventricular rate control in the acute setting is generally
accomplished with beta blockers or nondihydropyridine
calcium channel blockers (i.e., diltiazem or verapamil),
with digoxin reserved for patients with systolic HF or with
contraindications or inadequate response to other agents.
Of note, beta blockers and calcium channel blockers with
substantial negative inotropic effects, such as diltiazem or
verapamil, may precipitate or worsen HF in patients with
depressed EF or clinical HF. An additional beneﬁt of beta
blockers is that, compared with diltiazem, they may
accelerate the conversion of postoperative supraventric-
ular arrhythmias to sinus rhythm (326,327). Cardioversion
of minimally symptomatic AF/atrial ﬂutter is generally
not required until correction of the underlying problems
has occurred, which may lead to a return to normal sinus
rhythm. Intravenous amiodarone may also be used to aid
in restoring or maintaining sinus rhythm if its beneﬁts
outweigh the risk of hypotension and other side effects.
As with patients outside the perioperative setting, car-
dioversion of postoperative AF should be performed
when hemodynamic compromise is present.
Whereas numerous studies have been performed for
prophylaxis of AF in the setting of cardiac surgery,
comparatively few data exist in the setting of noncardiac
surgery. One RCT of 130 patients undergoing lung resec-
tion surgery showed that perioperative amiodarone
reduced the incidence of postoperative AF and reduced
length of stay compared with placebo (328). However, the
incidence of postoperative AF in the control group
(32.3%) was higher than that seen in a large national
database (12.6%) (321). Another RCT of 254 patients un-
dergoing lung cancer surgery also showed a signiﬁcant
reduction in postoperative AF with amiodarone but no
difference in length of stay or resource utilization
(329,330). An RCT of 80 patients undergoing esoph-
agectomy also showed a reduction in postoperative AF
but not in length of stay (331). Recommendations for
prophylaxis and management of postoperative AF after
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CPG (14).
If the patient develops a sustained, regular, narrow-
complex tachycardia (supraventricular tachycardia),
which is likely due to atrioventricular nodal reentrant
tachycardia or atrioventricular reciprocating tachycardia,
the supraventricular tachycardia frequently can be termi-
nated with vagal maneuvers or with intravenous medica-
tions (adenosine or verapamil). Most antiarrhythmic agents
(especially beta blockers, calcium channel blockers, and
class IC antiarrhythmic agents) can be used to prevent
further recurrences in the postoperative setting. Digoxin
and calcium channel blockers should be avoided in the
setting of pre-excited AF. The choice of individual agent
will depend on the nature of the arrhythmia and whether
the patient has associated structural heart disease. Recur-
rent supraventricular tachycardia is generally well treated
with catheter ablation therapy (92).
Asymptomatic premature ventricular contractions
generally do not require perioperative therapy or further
evaluation. Very frequent ventricular ectopy or runs of
nonsustained ventricular tachycardia may require anti-
arrhythmic therapy if they are symptomatic or result in
hemodynamic compromise (332). Patients with new-onset
postoperative complex ventricular ectopy, particularly
polymorphic ventricular tachycardia, should be evaluated
for myocardial ischemia, electrolyte abnormalities, or
drug effects. Ventricular arrhythmias may respond to
intravenous beta blockers, lidocaine, procainamide, or
amiodarone. Electrical cardioversion should be used for
sustained supraventricular or ventricular arrhythmias
that cause hemodynamic compromise. Patients with
ventricular arrhythmias in the setting of chronic cardio-
myopathy or inherited arrhythmia syndromes despite
GDMT should be evaluated for ICD therapy consistent
with existing CPGs (332–334).
Bradyarrhythmias that occur in the postoperative
period are usually sinus bradycardia secondary to some
other cause, such as medication, electrolyte or acid-base
disturbance, hypoxemia, or ischemia. Pain can also
heighten vagal tone, leading to sinus bradycardia and
even heart block, despite baseline normal conduction.
New atrioventricular block after noncardiac surgery is
rare. Sleep apnea may manifest as nocturnal bradycardia
in the postoperative setting. Acutely, bradycardia may
respond to atropine or aminophylline. Persistent symp-
tomatic bradyarrhythmias due to sinus node dysfunction
and atrioventricular block will respond to temporary
transvenous pacing. Indications for permanent pacing are
similar to those outside the perioperative setting
(333,335). Management of patients with pre-existing
pacemakers or ICDs is focused on restoring preoperative
settings for those patients who had preoperative reprog-
ramming. It is particularly important to ensure thattachytherapy in patients with ICDs has been restored
before discharge from the facility (336).
See Online Data Supplement 25 for additional informa-
tion on management of postoperative arrhythmias and
conduction disorders.6.4. Perioperative Management of Patients With CIEDs:
Recommendation
CLASS I
1. Patients with ICDs who have preoperative reprogramming to
inactivate tachytherapy should be on cardiac monitoring
continuously during the entire period of inactivation, and
external deﬁbrillation equipment should be readily available.
Systems should be in place to ensure that ICDs are reprog-
rammed to active therapy before discontinuation of cardiac
monitoring and discharge from the facility (336). (Level of
Evidence: C)
To assist clinicians with the perioperative evaluation and
management of patients with pacemakers and ICDs, the HRS
and the American Society of Anesthesiologists together
developed an expert consensus statement that was pub-
lished in July 2011 and endorsed by the ACC and the AHA
(33). Clinicians caring for patients with CIEDs in the periop-
erative setting should be familiar with that document and
the consensus recommendations contained within.
A central concern in perioperative management of pa-
tients with CIEDs is the potential for interaction between
the CIED and EMI, usually produced by monopolar elec-
trocautery (337). If the procedure involves only bipolar
electrocautery or harmonic scalpel or does not involve
electrocautery, then interaction with the CIED is
extremely unlikely, unless energy is applied directly to
the CIED generator or leads in the operative ﬁeld. With
monopolar electrocautery, the principal concern is that
EMI may cause transient inhibition of pacing in
pacemaker-dependent patients (usually those with com-
plete atrioventricular block) and/or inappropriate trig-
gering of shocks in patients with ICDs. With technological
advances in CIED hardware and ﬁltering, the potential for
more permanent adverse effects, such as electrical reset,
inadvertent reprogramming, or damage to the CIED
hardware or lead–tissue interface, has been largely
eliminated.
In advance of elective surgical procedures, a periopera-
tive CIED prescription should be developed by the clinician
or team that follows the patient in the outpatient setting
and communicated to the surgical/procedure team (Section
2.6). Depending on the patient’s underlying cardiac
rhythm, the type of CIED (pacemaker versus ICD), the
location of the operative procedure, and the potential for
EMI from electrocautery, the CIED prescription may
involve reprogramming a pacemaker or ICD to an asyn-
chronous pacing mode (i.e., VOO or DOO), reprogramming
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over the CIED, or no perioperative intervention (98,99).
Regardless of the CIED prescription, through advance
communication with the CIED follow-up outpatient
clinician/team, the surgical/procedure team should be
familiar with the type of CIED (pacemaker versus ICD), its
manufacturer, the response of the CIED to magnet appli-
cation, and the patient’s underlying cardiac rhythm.
External deﬁbrillation equipment with transcutaneous
pacing capability should be readily available in the oper-
ating room for patients with pacemakers or ICDs who are
having surgical procedures during which EMI or physical
disruption to the CIED system could occur. It is reason-
able to have a magnet available for all patients with a
CIED who are undergoing a procedure that could involve
EMI. All patients with CIEDs should have plethysmo-
graphic or arterial pressure monitoring during the proce-
dure, because electrocautery may interfere with
electrocardiographic recording and determination of the
patient’s cardiac rhythm.
A ﬁnal point concerns patients with ICDs who have
tachytherapies inactivated preoperatively. Such patients
are intrinsically more susceptible to perioperative ven-
tricular arrhythmias and should have continuous cardiac
monitoring during the entire period of ICD inactivation,
with external deﬁbrillation immediately available, if
needed. In addition, at least 3 deaths have been reported to
have been caused by failure to reactivate ICD tachy-
therapies in patients who had ICD therapy inactivated
preoperatively, and this problem is likely to be under-
reported (336). It is therefore imperative that surgical ser-
vices have systems in place to ensure that inactivated ICDs
are reprogrammed to active therapy before discontinua-
tion of cardiac monitoring and discharge from the facility.
See Online Data Supplement 26 for additional informa-
tion on perioperative management of patients with CIEDs.
7. ANESTHETIC CONSIDERATION AND
INTRAOPERATIVE MANAGEMENT
See Table 7 for a summary of recommendations for anes-
thetic consideration and intraoperative management.
7.1. Choice of Anesthetic Technique and Agent
See Online Data Supplement 27 for additional information
on choice of anesthetic technique and agent.
There are 4 main classiﬁcations of anesthesia: local
anesthesia, regional anesthesia (including peripheral
nerve blockade and neuraxial blockade), monitored
anesthesia care (typically using intravenous sedation with
or without local anesthesia), and general anesthesia
(which includes volatile-agent anesthesia, total intrave-
nous anesthesia, or a combination of volatile and intra-
venous anesthesia). The majority of the literature in thisﬁeld focuses on 1 of 3 areas with regard to preventing
perioperative myocardial adverse cardiac events.
7.1.1. Neuraxial Versus General Anesthesia
In patients for whom neuraxial anesthesia (epidural or
spinal anesthesia) is an option as the primary anesthetic
or as a supplement to general anesthesia, several factors,
such as the type of surgery, patient comorbidities, and
patient preferences, are crucial in determining risk versus
beneﬁts. A 2011 Cochrane review meta-analysis of 4
studies examining neuraxial anesthesia versus general
anesthesia for lower-limb revascularization found an
overall 4% MI rate in both groups (338). In 2001, an RCT of
abdominal aortic surgery patients comparing a thoracic
epidural/light general anesthesia technique with a gen-
eral anesthetic technique alone demonstrated no signiﬁ-
cant difference in myocardial ischemia and MI rates
between the groups (339). Therefore, in patients who are
eligible for an intraoperative neuraxial anesthetic, there is
no evidence to suggest a cardioprotective beneﬁt from the
use or addition of neuraxial anesthesia for intraoperative
anesthetic management. The evidence relating to neu-
raxial anesthesia/analgesia for postoperative pain control
is discussed in Section 7.2.
7.1.2. Volatile General Anesthesia Versus Total Intravenous
Anesthesia: Recommendation
CLASS IIa
1. Use of either a volatile anesthetic agent or total intravenous
anesthesia is reasonable for patients undergoing noncardiac
surgery, and the choice is determined by factors other than
the prevention of myocardial ischemia and MI (340,341).
(Level of Evidence: A)
Several studies have attempted to examine whether there is
a myocardial protective beneﬁt of volatile anesthetic use in
general anesthesia when compared with total intravenous
anesthesia (342). There is no evidence to suggest a difference
in myocardial ischemia/MI rates between the use of volatile
anesthesia and total intravenous anesthesia in patients un-
dergoing noncardiac surgery. Although the beneﬁt of using
volatile anesthetic agents has been demonstrated in cardiac
surgery, a reduction in myocardial ischemia or MI has not
been demonstrated in noncardiac surgery (343–347). A meta-
analysis of >6000 patients undergoing noncardiac surgery
failed to demonstrate a difference in MI rates between pa-
tients who received volatile anesthesia and patients who
received total intravenous anesthesia (340). However, the
event MI rate in the meta-analysis of >79 studies was 0 for
both groups. A randomized comparison of volatile anesthetic
administration versus total intravenous administration in
patients undergoing noncardiac surgery demonstrated no
difference in either myocardial ischemia or MI between the 2
groups (341).
TABLE 7 Summary of Recommendations for Anesthetic Consideration and Intraoperative Management
Recommendations COR LOE References
Volatile general anesthesia versus total intravenous anesthesia
Use of either a volatile anesthetic agent or total intravenous anesthesia is reasonable for patients undergoing
noncardiac surgery
IIa A (340,341)
Perioperative pain management
Neuraxial anesthesia for postoperative pain relief can be effective to reduce MI in patients undergoing
abdominal aortic surgery
IIa B (348)
Preoperative epidural analgesia may be considered to decrease the incidence of preoperative cardiac events
in patients with hip fracture
IIb B (349)
Prophylactic intraoperative nitroglycerin
Prophylactic intravenous nitroglycerin is not effective in reducing myocardial ischemia in patients undergoing
noncardiac surgery
III: No Beneﬁt B (292,355,356)
Intraoperative monitoring techniques
Emergency use of perioperative TEE in patients with hemodynamic instability is reasonable in patients
undergoing noncardiac surgery if expertise is readily available
IIa C N/A
Routine use of intraoperative TEE during noncardiac surgery is not recommended III: No Beneﬁt C N/A
Maintenance of body temperature
Maintenance of normothermia may be reasonable to reduce perioperative cardiac events IIb B (364,365)
Hemodynamic assist devices
Use of hemodynamic assist devices may be considered when urgent or emergency noncardiac surgery is
required in the setting of acute severe cardiac dysfunction
IIb C N/A
Perioperative use of pulmonary artery catheters
Use of pulmonary artery catheterization may be considered when underlying medical conditions that
signiﬁcantly affect hemodynamics cannot be corrected before surgery
IIb C N/A
Routine use of pulmonary artery catheterization is not recommended III: No Beneﬁt A (380–382)
COR indicates Class of Recommendation; LOE, Level of Evidence; MI, myocardial infarction; N/A, not applicable; and TEE, transesophageal echocardiogram.
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There are no RCTs to suggest a preference for monitored
anesthesia care over general anesthesia for reducing
myocardial ischemia and MI.
7.2. Perioperative Pain Management: Recommendations
CLASS IIa
1. Neuraxial anesthesia for postoperative pain relief can be
effective in patients undergoing abdominal aortic surgery to
decrease the incidence of perioperative MI (348). (Level of
Evidence: B)
CLASS IIb
1. Perioperative epidural analgesia may be considered to
decrease the incidence of preoperative cardiac events in
patients with a hip fracture (349). (Level of Evidence: B)
Pain management is fundamental to the care of the surgical
patient, and pain is one of many factors that can contribute
to the development of postoperative myocardial ischemia
and MI. Postoperative pain is associated with myocardial
ischemia; however, the best practices for perioperative
pain management have not been completely elucidated
(90,350–352). Most of the literature focusing on periopera-
tive myocardial events compares epidural analgesia withintravenous analgesia. Importantly, the potential efﬁcacy of
epidural analgesia depends on the local system of care. A
2003 review of a large billing registry comparing epidural
analgesia with other forms of analgesia failed to show a
reduction in perioperative myocardial events (353); how-
ever, other studies, including a meta-analysis of RCTs,
concluded that patients receiving epidural analgesia expe-
rienced a reduction in postoperative myocardial ischemia
and MI (348,354). An RCT in 2001 examining the use of
epidural anesthesia in patients undergoing abdominal sur-
gery found no difference between epidural and intravenous
analgesia in the prevention of perioperative MI, although a
subgroup analysis demonstrated a reduction in MI in pa-
tients undergoing abdominal aortic procedures (354). In
2012, a Cochrane review of 15 RCTs comparing epidural
analgesia with opioids for patients undergoing abdominal
aortic surgery reported a decrease in MIs in the patients
who received epidural analgesia (348). There is a paucity of
studies on perioperative cardiac events with regard to
various methods of pain control in the general surgical
population.
Although the majority of perioperative MIs occur dur-
ing the postoperative period, 1 RCT examined the inci-
dence of preoperative cardiac events in elderly patients
with hip fractures. The 64-patient study concluded that
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the incidence of preoperative myocardial ischemia and
preoperative MI, as well as HF and AF (349).
See Online Data Supplement 28 for additional informa-
tion on perioperative pain management.
7.3. Prophylactic Perioperative Nitroglycerin: Recommendation
CLASS III: NO BENEFIT
1. Prophylactic intravenous nitroglycerin is not effective in
reducing myocardial ischemia in patients undergoing
noncardiac surgery (292,355,356). (Level of Evidence: B)
There are no signiﬁcant studies within the past 10 years
examining the effect of prophylactic nitroglycerin on peri-
operative myocardial ischemia. Prior RCTs yielded conﬂict-
ing results and were small (<50 patients) and unblinded
(292,355,356).
See Online Data Supplement 29 for additional informa-
tion on prophylactic intraoperative nitroglycerin.
7.4. Intraoperative Monitoring Techniques: Recommendations
CLASS IIa
1. The emergency use of perioperative transesophageal echo-
cardiogram (TEE) is reasonable in patients with hemo-
dynamic instability undergoing noncardiac surgery to
determine the cause of hemodynamic instability when it
persists despite attempted corrective therapy, if expertise is
readily available. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. The routine use of intraoperative TEE during noncardiac
surgery to screen for cardiac abnormalities or to monitor
for myocardial ischemia is not recommended in patients
without risk factors or procedural risks for signiﬁcant he-
modynamic, pulmonary, or neurologic compromise. (Level
of Evidence: C)
TEE is widely available and commonly used perioperatively
in patients undergoing cardiac surgery. TEE has the capacity
to assess biventricular and valvular function, intracardiac
structures, the pericardial space, and the thoracic aorta
(17,357,358). The use of TEE intraoperatively in a patient
undergoing noncardiac surgery is less clear.
There are limited data evaluating intraoperative TEE
in the assessment of regional myocardial function and
any association with cardiac outcomes (359,360). More-
over, the data are insufﬁcient in terms of predictive ac-
curacy or cost-effectiveness to recommend routine TEE
monitoring. In contrast, emergency use of perioperative
TEE in patients with hemodynamic instability, to deter-
mine the cause of an unexplained, severe hemodynamic
instability that persists despite attempted corrective
therapy, is appropriate where available (27,29,361–363).
CPGs for the appropriate use of TEE have been devel-
oped by the American Society of Anesthesiologists,the Society of Cardiovascular Anesthesiologists, and
the American Society of Echocardiography (17,27,29).
Many anesthesiologists are experts in TEE; the use of
TEE by those with limited or no training should be
avoided (27).
7.5. Maintenance of Body Temperature: Recommendation
CLASS IIb
1. Maintenance of normothermia may be reasonable to reduce
perioperative cardiac events in patients undergoing noncar-
diac surgery (364,365). (Level of Evidence: B)
Hypothermia has been associated with several perioperative
complications, including wound infection, MACE, immune
dysfunction, coagulopathy, increased blood loss, death, and
transfusion requirements (365–372). However, interest is
emerging in the therapeutic beneﬁt of hypothermia in pres-
ervation of neurological function after head trauma, stroke,
and cardiac arrest. Balancing the risks and beneﬁts to
determine the appropriate use of hypothermia in the peri-
operative and inpatient hospital setting is an area of active
research.
There are 2 conﬂicting studies on hypothermia in
relation to perioperative cardiac events. They were con-
ducted in very different patient populations and with
different goals. In a 1997 study, 300 patients with known
cardiovascular disease or risk factors for cardiovascular
disease were randomized to forced air warmers or
ambient temperature. This study demonstrated a signiﬁ-
cantly higher incidence of a MACE (e.g., ischemia,
infarction, cardiac arrest) or an electrocardiographic
event, particularly ventricular tachycardia (365), in the
ambient-temperature group.
A large multicenter trial published in 2010 randomized
1000 patients with subarachnoid hemorrhage to either
normothermia or perioperative hypothermia to assess the
efﬁcacy of hypothermia in brain protection. This large
study demonstrated no increased incidence of cardio-
vascular events either intraoperatively or postoperatively
in the hypothermia-treated patients (364).
See Online Data Supplement 30 for additional informa-
tion on maintenance of body temperature.
7.6. Hemodynamic Assist Devices: Recommendation
CLASS IIb
1. Use of hemodynamic assist devices may be considered when
urgent or emergency noncardiac surgery is required in the
setting of acute severe cardiac dysfunction (i.e., acute MI,
cardiogenic shock) that cannot be corrected before surgery.
(Level of Evidence: C)
Rare case reports have noted the use of and complications
associated with hemodynamic assist device therapy during
noncardiac surgery. There are no published RCTs, retro-
spective reviews, meta-analyses, or case series of >10
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use of hemodynamic assist devices in patients at surgical
risk, and it is not recommended. That being said, the
number of patients chronically supported with long-term
implantable devices, including left, right, or biventricular
assist devices or total artiﬁcial heart, for advanced HF is
steadily increasing. While on mechanical circulatory sup-
port, patients may face medical problems requiring emer-
gency or nonemergency noncardiac surgery with varying
degrees of risk to the patient andmortality outcomes. Several
series have been published reporting outcomes in patients
with mechanical circulatory support undergoing noncardiac
procedures, with the 30-daymortality rate ranging from9% to
25% (373–379).
For perioperative management, a multidisciplinary
approach and expert guidance on anticoagulation strate-
gies, pump ﬂow control, hemodynamic monitoring,
infection, and bleeding prevention strategies are consid-
ered important. Speciﬁc recommendations on periopera-
tive management of these patients are addressed in the
International Society for Heart and Lung Transplantation
CPGs for mechanical circulatory support (379).
7.7. Perioperative Use of Pulmonary Artery Catheters:
Recommendations
CLASS IIb
1. The use of pulmonary artery catheterization may be consid-
ered when underlying medical conditions that signiﬁcantly
affect hemodynamics (i.e., HF, severe valvular disease, com-
bined shock states) cannot be corrected before surgery.
(Level of Evidence: C)
CLASS III: NO BENEFIT
1. Routine use of pulmonary artery catheterization in pa-
tients, even those with elevated risk, is not recommended
(380–382). (Level of Evidence: A)
The theoretical basis for better outcomes with the routine
use of pulmonary artery catheterization in noncardiac sur-
gery derives from clinicians’ improved understanding of
perioperative hemodynamics. Unfortunately, the clinical
trial data on which recommendations are made are sparse. Of
the 3 main trials, 2 are underpowered (380–382). The largest
trial randomly allocated the use of pulmonary artery cathe-
ters in 1994 patients at high surgical risk, deﬁned by an
American Society of Anesthesiologists risk score of III or IV
(380). In this trial, there were no differences in mortality or
morbidity, save for an increase in pulmonary embolism
noted in the pulmonary artery catheter arm. Therefore,
routine use of pulmonary artery catheterization in patients at
elevated surgical risk does not improve outcomes and is not
recommended.
See Online Data Supplement 31 for additional informa-
tion on perioperative use of pulmonary artery catheters.7.8. Perioperative Anemia Management
Anemia can contribute to myocardial ischemia, particu-
larly in patients with CAD. In patients with CAD who are
also anemic, ischemia can be triggered by both the lack
of adequate oxygen delivery to poststenotic myocar-
dium and a demand for increased cardiac output to
supply oxygen to other vascular beds throughout the
body. Transfusions to treat anemia are not without
economic costs and individual health costs, in the form
of an increased risk of infectious and noninfectious
complications. Transfusion practices vary widely, and
much of the literature attempts to address the clinical
question of when to transfuse an asymptomatic patient
below a preset hemoglobin level and when to transfuse
patients experiencing symptoms of ischemia. The 2012
American Association of Blood Banks CPG and a 2011
RCT provide some additional information and guidance
to clinicians navigating the complex interplay among
anemia, transfusions, and attribution of symptoms to
anemia (21,383).
In 2011, a RCT compared 2000 patients with either
CAD or known CAD risk factors and a hemoglobin
level <10 g/dL after hip fracture surgery who were
treated with either a liberal transfusion strategy
(hemoglobin <10 g/dL) or a conservative transfusion
strategy (hemoglobin <8 g/dL or symptoms of anemia)
(383). The endpoints of death and inability to walk at the
60-day follow-up were not found to be signiﬁcantly
different in either the liberal or conservative transfusion
group. Additionally, although the study found no dif-
ference in MI, unstable angina, or in-hospital death
between the 2 groups, it was not sufﬁciently powered to
show a difference in the aforementioned areas if a dif-
ference existed (383).
The 2012 American Association of Blood Banks CPG,
which is based on expert opinion and studies, recom-
mends a restricted transfusion strategy (hemoglobin
<7 g/dL to 8 g/dL) in asymptomatic, hemodynamically
stable patients without CAD (21). The CPG also recom-
mends adherence to a restrictive transfusion strategy in
hospitalized patients with cardiovascular disease and
consideration of transfusion for patients with symptoms
(e.g., chest pain, orthostasis, congestive HF) or
hemoglobin <8 g/dL (21). In postoperative patients, the
recommended maintenance hemoglobin concentration
is $8 g/dL, unless the patient exhibits symptoms. There
were no speciﬁc recommendations for hemodynamically
stable patients with acute coronary syndrome because of
the lack of high-quality evidence for either a liberal or a
restrictive transfusion strategy in these patients. The
consensus of those experts recommended a symptom-
guided approach to evaluating a hemoglobin level to
determine whether to transfuse a patient with anemia.
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8.1. Surveillance and Management for Perioperative MI:
Recommendations
CLASS I
1. Measurement of troponin levels is recommended in the
setting of signs or symptoms suggestive of myocardial
ischemia or MI (40,384). (Level of Evidence: A)
2. Obtaining an ECG is recommended in the setting of signs or
symptoms suggestive of myocardial ischemia, MI, or
arrhythmia (384,385). (Level of Evidence: B)
CLASS IIb
1. The usefulness of postoperative screening with troponin
levels in patients at high risk for perioperative MI, but
without signs or symptoms suggestive of myocardial
ischemia or MI, is uncertain in the absence of established
risks and beneﬁts of a deﬁned management strategy
(386–392). (Level of Evidence: B)
2. The usefulness of postoperative screening with ECGs in
patients at high risk for perioperative MI but without signs
or symptoms suggestive of myocardial ischemia, MI, or
arrhythmia, is uncertain in the absence of established
risks and beneﬁts of a deﬁned management strategy
(384,385,393–395). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine postoperative screening with troponin levels in un-
selected patients without signs or symptoms suggestive of
myocardial ischemia or MI is not useful for guiding periop-
erative management (40,384). (Level of Evidence: B)
Improvements in surgical outcomes and increasing difﬁculty
in accurately predicting adverse cardiovascular events and
death in patients before surgery have fostered efforts to
improve early detection of myocardial injury and MI to pre-
vent more serious complications. Routine screening with
troponin for cardiac injury has been proposed as a method of
early detection to ensure early intervention to avoid more
serious complications. Among the studies, elevations of
troponin of any level associate directly and consistently with
increases in 30-day mortality rates (40,384,396). In the
largest of the studies, the VISION (Vascular Events in
Noncardiac Surgery Patients Cohort Evaluation) trial (40),
troponin elevations predicted vascular and nonvascular
mortality rates equally. Type 1 MI (i.e., related to ischemia
from a primary coronary event, such as plaque rupture or
thrombotic occlusion) causes <5% of troponin elevation
postoperatively (384,396) and therefore constitutes a small
minority of the vascular causes of troponin elevation. In a
subsequent publication, the authors deﬁned myocardial
injury after noncardiac surgery as troponin elevation with or
without symptoms of myocardial ischemia (38). Myocardialinjury after noncardiac surgery is a novel classiﬁcation that
predicted 30-day mortality rate but diverges from the Third
Universal Deﬁnition of MI (397) by combining type 1 and type
2 events (i.e., type 2 is secondary to ischemia from a supply-
and-demand mismatch), despite their different pathophysi-
ological origin. In a study of 2232 consecutive patients
undergoing noncardiac surgery, 315 patients had elevation of
troponin I, 9.5% had attendant ECG changes suggestive of
cardiac ischemia, and 3.2% had typical chest pain showing
that a small minority of troponin elevation results from type
1 MI (396). Additionally, none of these studies accounts for
patients with troponin elevations before surgery, which may
be seen in as many as 21% of high-risk patients (398) and may
be even more common if high-sensitivity troponin assays are
used. Finally, the median time between troponin elevation
and death is >7 days after measurement, and none of the
studies clariﬁes the speciﬁc cause of death. In the absence of
a description of the speciﬁc cause of death and evidence for
the use of the biomarker to prevent these events, the use of
routine postoperative troponin measurement remains un-
certain, even in patients at high risk for perioperative MI.
Therefore, routine screening with troponin provides a
nonspeciﬁc assessment of risk, does not indicate a speciﬁc
course of therapy, and is not clinically useful outside of the
patient with signs or symptoms of myocardial ischemia or
MI. The value of postoperative troponin surveillance may be
clariﬁed after completion of MANAGE (Management of
Myocardial Injury After Noncardiac Surgery Trial), which is
testing the effects of 2 drugs (dabigatran and omeprazole)
that may prevent death, major cardiovascular complications,
and major upper gastrointestinal bleeding in patients who
have had myocardial injury after noncardiac surgery (399).
Of note, elevation in the MB fraction of creatine kinase may
also be used to detect myocardial necrosis and possible MI,
although its interpretation in the perioperative period is
often complicated by the signiﬁcant rise in overall creatine
kinase seen with noncardiac surgery.
The role of postoperative electrocardiography remains
difﬁcult to deﬁne. As noted in in previous versions of this
CPG, older studies have demonstrated that changes in the
ECG, particularly ST-segment changes, are associated
with increases in major cardiac complications—more than
2-fold compared with those without electrocardiographic
changes (400). More recently, however, it has become
clear that electrocardiography may not provide informa-
tion sufﬁcient for routine use. One study involved 337
vascular surgery patients in whom troponin I levels were
collected within 48 hours of surgery and 12-lead ECGs
were performed daily for 3 postoperative days (385). Forty
percent of the subjects had elevated troponin levels, but
ischemic changes on the ECG were noted in 6%. Whereas
elevations in troponin predicted death at 1 year, electro-
cardiographic changes did not. Several large surgical trials
have demonstrated the superiority of troponin testing to
Fleisher et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
ACC/AHA Perioperative Clinical Practice Guideline D E C E M B E R 9 , 2 0 1 4 : e 7 7 – 1 3 7
e116ECG in identifying patients with types 1 and 2 MI
(384,394) and suggest that troponin testing may be a su-
perior initial test in the diagnosis of MI. There are no
prospective randomized trials examining the value of
adding ECGs to routine postoperative care. In addition,
the interpretation of ECGs in the setting of critical illness
is only moderately reliable among expert readers (401).
The current use of ECGs may have developed as a method
to screen for MI when little else was routinely available.
In the absence of clinical trial data, a recommendation for
routine postoperative ECGs cannot be made.
See Online Data Supplement 32 for additional informa-
tion on surveillance and management for perioperative MI.
9. FUTURE RESEARCH DIRECTIONS
Current recommendations for perioperative cardiovascu-
lar evaluation and management for noncardiac surgery
are based largely on clinical experience and observational
studies, with few prospective RCTs. The GWC recom-
mends that future research on perioperative evaluation
and management span the spectrum from RCTs to
regional and national registries to focus on patient out-
comes. Development and participation in registries (such
as the American College of Surgeons NSQIP, American
Society of Anesthesiologists, and NACOR [National
Anesthesia Clinical Outcomes Registry]) for patients un-
dergoing noncardiac surgery will advance knowledge in
the following areas:
1. Surveillance: How are we doing across different prac-
tices? What are the signiﬁcant gaps in care?
2. Discovery: What new information can be learned? What
new strategies or interventions can improve these gaps
in care?
3. Translation: How can we best apply these strategies or
interventions to practice?
4. Dissemination: How can we spread what works?
The US healthcare system must focus on achieving the triple
aim of better patient care and experience, better population
health, and lower cost per capita over time. The use of peri-
operative tests and treatments improves patient outcomes
only when targeted at speciﬁc patient subsets. Implementa-
tion of ACC/AHA CPGs for perioperative cardiovascular
evaluation and management has been demonstrated to
improve patient outcomes and reduce costs (402–405). For
example, routine perioperative stress testing in patients at
low risk for cardiac events undergoing low-risk elective
noncardiac surgery has no beneﬁt, but it could have harm by
exposing the patient to unnecessary treatments, such as
medications or revascularization procedures. Alternatively,
the interruption of perioperative medications such as statins
and warfarin in situations not supported by evidence/peri-
operative CPGs can worsen patient outcomes (406).Diagnostic cardiovascular testing continues to evolve,
with newer imaging modalities being developed, such as
coronary calcium scores, computed tomography angiog-
raphy, and cardiac magnetic resonance imaging. The
value of these modalities in preoperative screening is
uncertain and warrants further study.
The use of perioperative beta blockers in beta–blocker-
naïve patients undergoing noncardiac surgery remains
controversial because of uncertainty about the following
issues: 1) optimal duration for the initiation of beta
blockers before elective noncardiac surgery; 2) optimal
dosing and titration protocol perioperatively to avoid
hemodynamic instability, including hypotension and
bradycardia; and 3) which elevated-risk patient subsets
would beneﬁt the most from initiation of perioperative
beta blocker. Although there is sufﬁcient evidence that
patients who are receiving long-term beta-blocker ther-
apy should continue beta blockers perioperatively, their
use in beta–blocker-naïve patients needs additional
research to illuminate the beneﬁt (avoidance of MI)
versus harm (stroke). RCTs are needed to demonstrate
when to start beta-blocker therapy before noncardiac
surgery, the optimal type and dose, and titration protocol.
The risk-adjusted mortality rates after noncardiac sur-
gery have declined signiﬁcantly in the past decade (relative
reductions of 11% to 19% for major cancer surgery and 36%
for abdominal aortic aneurysm repair), a development
that has been attributed to higher volumes, consolidation
of high-risk surgery at high-volume hospitals, and imple-
mentation of CPGs and local risk-reducing strategies (407).
Research also suggests that additional factors at the prac-
tice, clinician, and patient levels can impact patient out-
comes after noncardiac surgery. For bariatric surgery, the
technical skill of practicing surgeons assessed by peer rat-
ings varied widely, and greater skill was associated with
better patient outcomes. The bottom quartile of surgical
skill was associated with higher complication rates than
was the top quartile (14.5% versus 5.2%; p<0.001) (408).
As outlined in Section 8, the evidence base for the pre-
dictive value of biomarkers in the perioperative period has
grown. However, the utility of this information in inﬂuencing
management and outcome is unknown and is currently un-
dergoing investigation. The results of these investigations
could lead to changes in recommendations in the future.
To implement the recommendations of the current
perioperative CPGs effectively, a “perioperative team
approach” is needed. The perioperative team is intended
to engage clinicians with appropriate expertise; enhance
communication of the beneﬁts, risks, and alternatives;
and include the patient’s preferences, values, and
goals. Members of the perioperative team would
include the patient and family, surgeon, anesthesiologist,
cardiologist, hospitalist, primary care clinician, and
additional clinicians (e.g., a congenital heart disease
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e117specialist) depending on the unique circumstances of the
patient. Shared decision making aims to take into account
the patient’s preferences, values, and goals and is useful
for treatment decisions where there are alternatives with
comparable outcomes or where patient action is needed,
such as medication adherence. Future research will also
be needed to understand how information on periopera-
tive risk is incorporated into patient decision making.
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e136APPENDIX 3. RELATED RECOMMENDATIONS FROM OTHER CPGSs From the 2011 CABG and PCI CPGsTABLE A Left Main CAD Revascularization RecommendationAnatomic Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (409–411)
CABG and PCI IIa—Calculation of the STS and SYNTAX scores B (296,409,412–418)
UPLM*
CABG I B (419–425)
PCI IIa—For SIHD when both of the following are present: B (412,414,418,426–444)
2. Anatomic conditions associated with a low risk of PCI procedural
complications and a high likelihood of good long-term outcome
(e.g., a low SYNTAX score of #22, ostial, or trunk left main CAD)
3. Clinical characteristics that predict a signiﬁcantly increased risk of adverse
surgical outcomes (e.g., STS-predicted risk of operative mortality$5%)
IIa—For UA/NSTEMI if not a CABG candidate B (412,432–435,
440,441,443–445)
IIa—For STEMI when distal coronary ﬂow is TIMI ﬂow grade <3 and PCI can be
performed more rapidly and safely than CABG
C (429,446,447)
IIb—For SIHD when both of the following are present: B (412,414,418,
426–444,448)2. Anatomic conditions associated with a low-to-intermediate risk of PCI
procedural complications and intermediate-to-high likelihood of good
long-term outcome (e.g., low–intermediate SYNTAX score of <33,
bifurcation left main CAD)
3. Clinical characteristics that predict an increased risk of adverse surgical
outcomes (e.g., moderate–severe COPD, disability from prior stroke, or
prior cardiac surgery; STS-predicted risk of operative mortality >2%)
III: Harm—For SIHD in patients (versus performing CABG) with
unfavorable anatomy for PCI and who are good
candidates for CABG
B (412,414,418–425,
427,428)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (421,425,449–452)
IIa—It is reasonable to choose CABG over PCI in patients with complex 3-vessel
CAD (e.g., SYNTAX >22) who are good candidates for CABG
B (428,443,451,453,454)
PCI IIb—Of uncertain beneﬁt B (421,442,449,451,455)
2-vessel disease with proximal LAD artery disease*
CABG I B (421,425,449–452)
PCI IIb—Of uncertain beneﬁt B (421,449,451,455)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (456–459)
IIb—Of uncertain beneﬁt without extensive ischemia C (451)
PCI IIb—Of uncertain beneﬁt B (421,449,451,455)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term beneﬁt B (425,451,460,461)
PCI IIb—Of uncertain beneﬁt B (421,449,451,455)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (425,449,456,457,
462–465)
PCI III: Harm B (425,449,456,457,
462–465)
LV dysfunction
CABG IIa—EF 35% to 50% B (425,466–470)
CABG IIb—EF <35% without signiﬁcant left main CAD B (425,466–472)
PCI Insufﬁcient data N/A
Continued on the next page
TABLE A Continued
Anatomic Setting COR LOE References
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (473–475)
PCI I C (474)
No anatomic or physiological criteria for revascularization
CABG III: Harm B (425,449,456,457,
462–465,476)
PCI III: Harm B (425,449,456,457,
462–465,476)
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI (458,477–484) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; CPG, clinical practice
guideline; EF, ejection fraction; LAD, left anterior descending; LIMA, left internal mammary artery; LOE, Level of Evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous
coronary intervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM,
unprotected left main disease; and VT, ventricular tachycardia.
Reproduced from Levine et al. (26) and Hillis et al. (25).
TABLE B GDMT Recommendations for Beta Blockers From 2011 Secondary Prevention CPG
Beta Blockers Class I
1. Beta-blocker therapy should be used in all patients with LV systolic dysfunction (EF #40%) with HF or prior MI, unless contraindicated.
(Use should be limited to carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality.) (485–487).
(Level of Evidence: A)
2. Beta-blocker therapy should be started and continued for 3 years in all patients with normal LV function who have had MI or ACS (488–490).
(Level of Evidence: B)
Class IIa
1. It is reasonable to continue beta blockers >3 years as chronic therapy in all patients with normal LV function who have had MI or
ACS (488–490). (Level of Evidence: B)
2. It is reasonable to give beta-blocker therapy in patients with LV systolic dysfunction (EF #40%) without HF or prior MI. (Level of Evidence: C)
ACS indicates acute coronary syndrome; CPG, clinical practice guideline; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; LV, left ventricular; and MI,
myocardial infarction.
Reproduced from Smith Jr et al. (249)
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e137APPENDIX 4. ABBREVIATIONSAC
AC
AF
AR
AR
AS
AV
BM
CA
CA
CI
CIE
CP
DA
DE
DS
EC
EF
EM
ER
GD
GW
HF
ICD
LV
LV
MA
ME
MI
MP
MR
OR
PC
RC
RV
TA
TEE ¼ angiotensin-converting enzyme
HD ¼ adult congenital heart disease
¼ atrial ﬁbrillation
¼ aortic regurgitation
B ¼ angiotensin-receptor blocker
¼ aortic stenosis
R ¼ aortic valve replacement
S ¼ bare-metal stent
BG ¼ coronary artery bypass graft
D ¼ coronary artery disease
¼ conﬁdence interval
D ¼ cardiovascular implantable electronic device
G ¼ clinical practice guideline
PT ¼ dual antiplatelet therapy
S ¼ drug-eluting stent
E ¼ dobutamine stress echocardiogram
G ¼ electrocardiogram
¼ ejection fraction
I ¼ electromagnetic interferenceC ¼ Evidence Review Committee
MT ¼ guideline-directed medical therapy
C ¼ guideline writing committee
¼ heart failure
¼ implantable cardioverter-deﬁbrillator
¼ left ventricular
EF ¼ left ventricular ejection fraction
CE ¼ major adverse cardiac event
T ¼ metabolic equivalent
¼ myocardial infarction
I ¼ myocardial perfusion imaging
¼ mitral regurgitation
¼ odds ratio
I ¼ percutaneous coronary intervention
T ¼ randomized controlled trial
¼ right ventricular
VR ¼ transcatheter aortic valve replacement
E ¼ transesophageal echocardiogram
